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A B S T R A C T
Obesity, a chronic state of energy overload, is characterized by adipose tissue dysfunction that is considered to
be the major driver for obesity associated metabolic complications. The reasons for adipose tissue dysfunction
are incompletely understood, but one potential contributing factor is adipose tissue mitochondrial dysfunction.
Derangements of adipose tissue mitochondrial biogenesis and pathways associate with obesity and metabolic
diseases. Mitochondria are central organelles in energy metabolism through their role in energy derivation
through catabolic oxidative reactions. The mitochondrial processes are dependent on the proper NAD+/NADH
redox balance and NAD+ is essential for reactions catalyzed by the key regulators of mitochondrial metabolism,
sirtuins (SIRTs) and poly(ADP-ribose) polymerases (PARPs). Notably, obesity is associated with disturbed
adipose tissue NAD+ homeostasis and the balance of SIRT and PARP activities. In this review we aim to
summarize existing literature on the maintenance of intracellular NAD+ pools and the function of SIRTs and
PARPs in adipose tissue during normal and obese conditions, with the purpose of comprehending their
potential role in mitochondrial derangements and obesity associated metabolic complications. Understanding
the molecular mechanisms that are the root cause of the adipose tissue mitochondrial derangements is crucial
for developing new eﬀective strategies to reverse obesity associated metabolic complications.
1. Introduction
Adipose tissue is the most plastic organ in the body, with an ability
to enlarge and contract several-fold in response to alterations in energy
balance. This process requires ﬁne-tuned regulation of the number of
adipocytes through adipogenesis of new and removal of nonviable cells,
and the size of the existing adipocytes through lipogenesis and lipolysis.
In addition, the other cell types present in adipose tissue namely the
preadipocytes, ﬁbroblasts, endothelial cells and immune cells must
work in concert with the adipocytes to support proper adipose tissue
function and homeostasis. Adipose tissue can be categorized into white
and brown adipose tissue (WAT and BAT, respectively) based on cell
morphology and tissue function. While brown adipocytes have multiple
lipid droplets and are rich in mitochondria, enough to contribute
to their brown color, white adipocytes have a unilocular lipid
droplet with relative rarefaction of mitochondria and other cytosolic
organelles.
The primary function of WAT is considered to be to buﬀer whole
body energy balance through lipid handling, whereas BAT is specialized
to produce heat by an energy dissipating process of non-shivering
thermogenesis – both relevant for systemic energy balance home-
ostasis. Moreover, adipose tissue secretes hormones and adipocyto-
kines that aﬀect metabolic health through systemic eﬀects on the
metabolism of other tissues. Adipose tissue needs to continuously
respond to physiological stimuli, such as alterations in energy yield,
fasting and meals (WAT), or cold exposure (BAT). In these responses,
adipose tissue mitochondria are relevant organelles for both the energy
handling and endocrine function [1,2]. Thus it is perhaps not surpris-
ing that activity of adipose tissue mitochondria seems to be especially
important for the maintenance of whole-body metabolic health,
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characterized by high insulin sensitivity, low liver fat, and absence of
low-grade inﬂammation [3,4].
According to the adipose tissue expandability hypothesis [5,6], the
root cause for ectopic lipid accumulation is the inability of the adipose
tissue to enlarge and handle excess nutrients leading to lipid spill over
to ectopic sites (such as to the liver and muscle) and to the systemic
lipotoxic insults [6]. Interestingly, subsequent studies have demon-
strated that downregulation of mitochondrial pathways in adipose
tissue correlates with hepatic steatosis and insulin resistance [7]. Thus,
mitochondrial dysfunction may be the underlying reason for the
adipose tissue expandability problem. In line with this notion, adipose
tissue derived stem cells from obese individuals have reduced prolif-
erative capacity and loss of viability [8]. As a source of building blocks
for biosynthetic processes and ATP, mitochondrial metabolism is
essential for active adipocyte proliferation and diﬀerentiation for tissue
maintenance and expansion [9]. Moreover, earlier global transcrip-
tomics results showed that pathways regulating adipocyte diﬀerentia-
tion, together with mitochondrial oxidative metabolism, were signiﬁ-
cantly downregulated in obese adipose tissue [7], especially in the
metabolically unhealthy obese subjects [10]. Thus, loss of mitochon-
drial function may result in reduction of adipogenic capacity and
maintenance of mature adipocytes, which can contribute to cell death,
inﬂammation and global adipose tissue dysfunction. This mitochon-
drial downregulation may also explain the paradox why adipose cell
diﬀerentiation and storage of triglycerides has been proposed to be
hampered in obesity [7,11,12].
Mitochondria are thus key organelles in several fundamental
aspects of adipose tissue physiology. Mitochondrial metabolic pro-
cesses are largely dependent on the NAD+/NADH redox couple, and
the disruption of NAD+ homeostasis as well as mitochondrial dysfunc-
tion have been suggested to be major causes for obesity and metabolic
complications. Mitochondrial metabolism is regulated via two NAD+-
dependent enzyme families, sirtuins (SIRTs) and poly(ADP-ribose)
polymerases (PARPs), which have opposing eﬀects on metabolism
[13,14]. Until now, most studies on SIRTs and PARPs have been
performed in nonadipose tissue and mouse models. Less is known
about their functions in adipose tissue or in obesity, especially in
humans. The purpose of this review is to discuss the NAD+/NADH
redox couple dependent mitochondrial pathways in obesity and the
maintenance of adequate NAD+ homeostasis in adipose tissue.
Moreover, we will present the current knowledge of SIRTs and
PARPs in adipose tissue and elucidate what is known about their role
in mitochondrial metabolism, obesity and metabolic health.
2. Mitochondrial metabolism and obesity
2.1. Mitochondrion as an organelle
Mitochondria are essential organelles of eukaryotic organisms and
are present in all nucleated mammalian cells. They are double
membrane bound subcellular structures where the membranes line
two distinct compartments: the matrix within the inner membrane and
the intermembrane space between the two membranes. Mitochondria
possess their own genome, mitochondrial DNA (mtDNA), which
encodes for 13 proteins essential for the function of the organelle
and the RNA molecules for their translation. However, as over a 1000
proteins have been found in mitochondria [15], the majority of them
are encoded in the nucleus and the proteins are imported into
mitochondria after synthesis in the cytosol, thus, necessitating a
uniquely coordinated eﬀort of the nuclear mitochondrial genes and
mtDNA encoded genes for proper mitochondrial function.
Mitochondria are highly dynamic structures and their morphology,
which is relevant for function, can vary from fragmented separate
mitochondria to elongated interconnected reticulum depending on the
cell type or tissue and physiological signals [16]. The morphology is
determined by the balance of fusion and ﬁssion events mediated by a
set of dedicated GTPase proteins, namely optic atrophy 1, mitofusin 1
and mitofusin 2 for fusion and dynamin-1-like for ﬁssion. Moreover,
mitochondria form functionally relevant and stable contacts with other
subcellular organelles, especially the endoplasmic reticulum. These
contacts with the endoplasmic reticulum have recently been shown to
participate in determination of mitochondrial morphology through
mitochondrial ﬁssion [17].
In addition to morphology, mitochondrial mass and activity,
determined by the balance of mitochondrial biogenesis and turnover,
vary greatly between diﬀerent tissues and in response to physiological
signals. The biogenesis of mitochondria is a tightly regulated process.
Key regulators in coordinating mitochondrial biogenesis and metabo-
lism in response to physiological demand are two co-transcriptional
regulators, peroxisome proliferator-activated receptor gamma coacti-
vator 1-alpha (PGC-1α) and nuclear receptor co-repressor 1, which
have opposing eﬀects on mitochondrial biogenesis and oxidative
metabolism. While PGC-1α increases mitochondrial biogenesis and
oxidative metabolism during conditions of increased cellular energy
demands, such as exercise and cold exposure, [18–20], nuclear
receptor co-repressor 1 represses mitochondrial biogenesis during
energy excess [21–23]. These regulators aﬀect several transcription
factors, the peroxisome proliferator-activated receptor (PPAR) and
estrogen related receptor families for example, to regulate gene
expression of mitochondrial genes [24].
Less is known about mitochondrial turnover, which is governed by
several processes. Mitochondrial proteins can be degraded through
proteases within the mitochondria and by the proteasome system on
the mitochondrial outer membrane [25,26]. If the proteolytic system is
overwhelmed or mitochondrial proteostasis is otherwise disrupted, a
protective stress response called the mitochondrial unfolded protein
response is triggered. The mitochondrial unfolded protein response
leads to upregulation of mitochondrial chaperones and proteases to
alleviate the stress [27]. Mitochondria can also bud oﬀ vesicles
containing proteins destined for degradation in the lysosomes [28].
Furthermore, degradation of entire organelles through macroauto-
phagy (referred to as mitophagy) has been described. During mito-
phagy damaged mitochondria are segregated from the mitochondrial
network and targeted for degradation through a mechanism dependent
on PTEN-induced putative kinase 1 and E3 ubiquitin ligase parkin
proteins [29]. However, the relative contribution of these various
mechanisms to turnover of mitochondria in vivo in diﬀerent tissues
is at present unclear.
2.2. Mitochondrial metabolism and NAD+/NADH redox reactions
Mitochondria have many important functions in the cell, but given
the scope of this review, we will here focus on their vital role in cellular
energy and metabolic homeostasis. One of the most prominent
mitochondrial functions is oxidative metabolism, in which carbon fuels
from food (carbohydrates, proteins and fats) are catabolized and
converted to ATP, the major cellular energy currency, through mito-
chondrial respiration. ATP is also produced in the cytosol through
glycolysis, but mitochondrial oxidative energy production is more
eﬃcient than anaerobic energy metabolism. Both anaerobic and
aerobic metabolism rely on the NAD+/NADH redox couple for the
production of energy. In these reactions NAD+ accepts a hydride ion
(H-) from the coupled reactant, reducing NAD+ consequently to NADH
and oxidizing the reactant. The role of NAD+ in transferring hydrogen
in biochemical reactions was ﬁrst discovered almost 100 years ago by
Otto Warburg and colleagues [30].
In the cytoplasm, aerobic glycolysis requires two NAD+ molecules to
convert one glucose molecule to pyruvate (Fig. 1) [31]. In this process
glucose is ﬁrst converted to two glyceraldehyde-3-phosphate molecules
and successively oxidized into 1–3-biphosphoglycerate by glyceralde-
hyde-3-phosphate dehydrogenase. In parallel, glyceraldehyde-3-phos-
phate dehydrogenase reduces NAD+ to NADH. Through a few inter-
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mediate steps 1–3-biphosphoglycerate is converted to pyruvate, which is
then directed to mitochondria for aerobic respiration, i.e. glucose
oxidation. In mitochondria, pyruvate undergoes irreversible oxidative
decarboxylation, catalyzed by pyruvate dehydrogenase complex, result-
ing in the formation of acetyl-CoA and the reduction of NAD+ to NADH.
As the mitochondrial inner membrane is impermeable to both NAD+
and NADH, NADH is transferred into the mitochondria via either the
malate-aspartate or the glycerol-3-phosphate shuttles [32].
In addition to glucose oxidation, acetyl-CoA and NADH can be
generated from fatty acids through β-oxidation (Fig. 1) [33]. Fatty acids
Fig. 1. Adipose tissue metabolic and mitochondrial pathways in white (A) and brown (B) adipose tissue. Pyruvate and fatty-acyl-carnitines derived from glycolysis and break-down of
fatty acids, respectively, enter the mitochondria where they are further catabolized to acetyl-CoA by the pyruvate dehydrogenase complex and beta-oxidation. The acetyl-CoA enters the
TCA cycle and the high-energy electrons derived from the TCA cycle are used to power ATP production through oxidative phosphorylation (OXPHOS). Citrate derived from the TCA cycle
is used a precursor for lipogenesis. In white adipose tissue, acetyl-CoA and succinyl-CoA derived from branched chain amino acid (BCAA) catabolism also enter the TCA cycle (A). In
brown adipose tissue, the uncoupling proteins (UCPs) induce thermogenesis by uncoupling mitochondrial respiration from ATP production (B). Pathways downregulated by obesity are
highlighted in blue. CS; citrate synthase, FA; fatty acid, FOXO1; forkhead box O1, GAPDH; glyceraldehyde-3-phosphate dehydrogenase, mtDNA;mitochondrial DNA, PARP; poly(ADP-
ribose) polymerases, PGC-1α; peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARγ; peroxisome proliferator-activated receptor gamma, PRDM16; PR domain
containing 16, SDH; succinate dehydrogenase, SIRT; sirtuin, TCA; tricarboxylic acid, TF; transcription factor and TG; triglycerides.
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are conjugated with a CoA group in the cytosol, converted to long-chain
acyl carnitine to be transported across the mitochondrial membranes
and converted back to long-chain acyl-CoA, which enters the fatty acid
β-oxidation pathway, i.e. degradation of acyl-CoA to acetyl-CoA. One
cycle of β-oxidation is a four-step process during which acetyl-CoA,
NADH, FADH2 and new two carbons shorter acyl-CoA are produced.
The acetyl-CoA produced either through glucose oxidation or fatty
acid β-oxidation is directed to the mitochondrial tricarboxylic acid
(TCA) cycle, the ﬁnal common pathway for oxidation of fuel molecules
(Fig. 1). In the TCA cycle, in concert with other enzymatic reactions
isocitrate dehydrogenase, α-ketoglutarate dehydrogenase and malate
dehydrogenase oxidize their substrates and at the same time reduce
NAD+ to NADH [34].
Finally, the high-energy electrons derived from the TCA cycle
carried by NADH and FADH2 are sequentially transferred through
the respiratory chain complexes (Fig. 1) [31] and their energy is used to
generate a proton motive force across the inner mitochondrial mem-
brane by coupling the electron transport to pumping of protons across
the inner mitochondrial membrane by complexes I, III and IV. This
electrochemical gradient is utilized by the ATP synthase to generate
ATP in oxidative phosphorylation (OXPHOS). In the respiratory chain,
the oxidation of NADH by complex I yields NAD+.
Mitochondria are also central for other metabolic processes. One of
them is catabolism of branched chain amino acids (BCAAs), valine,
leucine and isoleucine. BCAAs are ﬁrst deaminated to α-ketoacids and
subsequently converted into TCA cycle intermediates acetyl-CoA or
succinyl-CoA through oxidative reactions that yield NADH (Fig. 1A)
[35]. In addition to its role in oxidative metabolism, the TCA cycle is an
essential anabolic pathway providing precursor carbon metabolites for
biosynthetic processes, such as citrate for fatty acid and sterol synth-
esis, and oxaloacetate and α-ketoglutarate for non-essential amino acid
synthesis [31].
Overall, many of the metabolic reactions in mitochondria are
dependent on the NAD+/NADH redox couple. Thus, disruption of the
cellular NAD+/NADH homeostasis has the potential to cause pervasive
disturbances in mitochondrial function and metabolism.
3. Obesity-associated adipose tissue mitochondrial
derangements
3.1. WAT derangements
The relatively low abundance of mitochondria in white adipocytes
has led to the underestimation of their role in WAT. However, quite
recently, the WAT mitochondrial function has gained more interest,
especially after the notion that mitochondrial biogenesis and oxidative
functions are downregulated in human subcutaneous WAT in obesity
[11]. Importantly, downregulation of mitochondrial oxidative path-
ways in obesity was recapitulated in isolated mature adipocytes [36],
showing that despite their assumed primary function as lipid storage,
white adipocytes do have an important oxidative role in regulating the
energy balance. As mentioned before, mitochondrial transcriptional
downregulation in WAT has been closely linked to metabolically
unhealthy obese phenotypes [10] and may thus have an eﬀect on the
development of metabolic disturbances in obesity.
The majority of the data available from mouse and human studies
show that mitochondrial mass is reduced in obese WAT. Mitochondrial
mass in tissues is assessed through analysis of several parameters
including relative mtDNA copy number, protein amount of mitochon-
drial proteins and transmission electron microscopy based evaluation
of mitochondrial area. The copy number of mtDNA is reduced in
genetic mouse models of obesity, human obese diabetic patients, the
heavier co-twin of monozygotic twins discordant for BMI, and corre-
lates inversely with BMI (Fig. 1) [1,7,11,37–39]. A reduction in the
WAT OXPHOS subunit protein amount is also seen in high-fat diet
(HFD) and genetically induced obesity in mice, in the heavier mono-
zygotic twins compared to their leaner co-twins and in isolated
adipocytes from obese individuals [1,11,36,38,40]. Moreover, a reduc-
tion in mitochondrial size or total area within the adipocytes was
observed by transmission electron microscopy analysis in obese and
obese diabetic mice, respectively [38].
To link changes in mitochondrial mass to biogenesis and turnover, the
gene expression and protein levels of key regulators in these pathways
have been analyzed. In mice, the expression of PGC-1α is reduced in WAT
in both HFD and genetically induced obesity (Fig. 1) [40,41]. Moreover,
PGC-1α expression is diminished in both WAT and isolated adipocytes of
the heavier co-twin of BMI discordant monozygotic twins [11,36] and in
obese diabetic patients [37], indicating a reduced activity of the mito-
chondrial biogenesis program. Data on mitochondrial turnover in obese
WAT are less clear. In HFD induced obese mouse WAT, the protein levels
of mitophagy markers including PTEN-induced putative kinase 1 and E3
ubiquitin ligase parkin are increased, indicating increased mitochondrial
turnover [40]. In contrast, WAT mRNA levels of the same markers
correlate inversely with body weight and positively with insulin sensitivity
in mice [42]. Current data on the mitochondrial unfolded protein
response pathway in obese WAT is also limited, but expression level of
genes in this pathway were decreased in the heavier co-twin of BMI
discordant monozygotic twins [43], and increased by treatment with anti-
diabetic medication in WAT of obese diabetic mice [41].
Transcriptomics analyses of WAT in obesity have consistently
shown a global downregulation of gene expression in pathways related
mitochondrial metabolism and function, such as OXPHOS, fatty acid
beta-oxidation and BCAA catabolism (Fig. 1A), in both mouse models
and humans. In mice, HFD and genetically induced obesity led to
reduction in gene expression in mitochondrial pathways including the
TCA cycle, OXPHOS, fatty acid beta-oxidation and BCAA catabolism in
WAT [41,44,45]. In diabetic obese patients, genes in OXPHOS pathway
were downregulated in both visceral and subcutaneous WAT [46]. In
healthy monozygotic BMI discordant twins, many mitochondrial path-
ways including the TCA cycle, OXPHOS, fatty acid beta-oxidation and
BCAA catabolism are downregulated in the heavier co-twin [7,11], and
the downregulation of OXPHOS and BCAA catabolism is also seen in
isolated adipocytes of the heavier co-twin [36]. Global proteomics
analysis supports the transcriptomics ﬁndings of downregulation of
mitochondrial pathways [47,48]. Hence, it seems clear that obesity
leads to a systemic downregulation of mRNA and protein level
expression in mitochondrial pathways in both mice and humans.
The key enzyme of the mitochondrial TCA cycle, citrate synthase
(Fig. 1A), catalyzes the formation of citrate that is used as a precursor
for fatty acid synthesis. The activity of citrate synthase is often used as
a marker for mitochondrial mass, but given the role of this enzyme in
fatty acid metabolism, it is likely that its abundance and activity is
regulated by HFD/obesity and should thus be considered separately.
The activity of citrate synthase is reduced in HFD and genetically
induced obesity mouse models, and it should be noted that mtDNA
copy number was not signiﬁcantly altered in these models [40,41].
Reduced citrate synthase activity has also been demonstrated in
mitochondria of both subcutaneous and visceral adipocytes of obese
humans [49–51], but no diﬀerence in citrate synthase activity in
mitochondria isolated from subcutaneous WAT between lean con-
trols, obese or obese diabetic patients has also been reported [52].
Despite this discrepancy the majority of the existing data support a
reduction of citrate synthase activity in obese WAT in mice and
humans.
The mitochondrial oxidative capacity has also been directly as-
sessed in WAT. A recent study used high-resolution respirometry to
show reduced respiration capacity in mitochondria isolated from both
subcutaneous and visceral adipocytes of several genetically and HFD
induced obesity mouse models, providing strong evidence for impaired
WAT mitochondrial oxidative capacity in obesity (Fig. 1A) [53]. These
results are in agreement with previous studies that showed reduced
oxygen consumption and fatty acid oxidation rate when normalized to
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cell number in white adipocytes isolated from obese mice [38,54].
However, no alterations in basal oxygen consumption levels has been
reported when measured from WAT explants and normalized to tissue
mass [40]. Most human studies show that respiration or enzymatic
activities of the respiratory chain complexes are reduced in isolated
mitochondria from obese subcutaneous adipocytes and adipose tissue
[50,51] or visceral adipocytes [51]. Recent ﬁndings examining pre-
adipocytes isolated from mouse and human WAT in cell culture setting
indicate that the obesity-associated defects in mitochondrial respira-
tion persist in cell culture [8].
Overall, the association between mitochondrial abnormalities in WAT
and obesity is strong, but the causal pathogenic relationship and whether
mitochondria are per se defective or if mitochondrial dysfunction is a
reﬂection of decreased mitochondrial content is uncertain. Based on the
limited number of studies showing impaired mitochondrial respiration in
isolated mitochondria, it appears probable that functional defects intrinsic
to mitochondria are present in obese WAT in addition to decreased
content. Interestingly, acquired obesity associates with impaired mito-
chondrial biogenesis and low mitochondria number in young metaboli-
cally healthy monozygotic obesity-discordant twin pairs [11]. Thus, we
suspect that mitochondrial abnormalities precede the development of
metabolic syndrome in obese subjects.
3.2. BAT derangements
BAT is abundant and active in small rodents and newborn humans
but also in adult humans upon cold exposure [55,56]. Brown adipo-
cytes regulate body temperature via thermogenesis by uncoupling ATP
synthesis from OXPHOS (Fig. 1B), and thus, dissipating energy as heat.
An essential gene for the induction of thermogenic response and
characteristic of brown adipocytes is uncoupling protein 1 (UCP1)
(Fig. 1B). Its transcription is activated by the co-operation of the
transcriptional regulators PGC-1α, PPARγ and PR domain containing
16 (Prdm16), which also promote the expression of the fatty acid
oxidation and respiratory complex subunit genes in BAT [57–59].
Obesity is characterized by impaired function, enlargement and
whitening of BAT, as evidenced by several animal and human studies
[60–63]. Impaired function of BAT in obesity has been proposed to be
caused by the rarefaction of vasculature and development of hypoxia
[62]. The impaired BAT function is described by diminished β-
adrenergic signaling, reduction of thermogenesis and the UCP1 protein
amount, decreased mitochondrial content, and impaired respiratory
complex activities (Fig. 1B) [62,64]. This results in the formation of a
large, unilocular lipid droplet in brown adipocytes, and hence, in-
creased brown adipocyte size and expansion of the overall tissue size
giving obese BAT a whitened appearance.
4. The maintenance of NAD+ homeostasis in adipose tissue
4.1. Introduction
As discussed in the previous section, obesity is characterized with
derangements of mitochondrial metabolism. As many of the mitochon-
drial enzymatic pathways rely on the redox couple NAD+/NADH, it is
not surprising that obesity was recently noticed to associate with
deteriorated NAD+ metabolism in adipose tissue in mice [65–67] and
humans [68,69]. Thus, the preservation of adequate NAD+ homeostasis
is most likely essential for the function of adipose tissue mitochondrial
metabolism and metabolic health. In the next section, we will thus
discuss intracellular NAD+ pools, NAD+ biosynthesis and consumption
pathways, and potential NAD+ boosting strategies in obesity.
4.2. Intracellular NAD+ levels and compartmentalization
Total intracellular NAD+ levels are normally maintained around
50 pmol/mg tissue in mouse WAT whereas NAD+ levels are markedly
higher (approximately 100–500 pmol/mg tissue) in mouse BAT and
other peripheral tissues [70,71]. There are four diﬀerent subcellular
NAD+ compartments inside the mammalian cell: nuclear/cytosolic,
mitochondrial, peroxisomal and endoplasmic reticulum/golgi [72].
Nuclear and cytosolic pools of NAD+ are considered to form one
combined pool as NAD+ has been suggested to be freely exchangeable
between these two cell compartments. As mitochondrial membrane is
impermeable to NAD+, the mitochondrial and nuclear/cytoplasmic
NAD+ pools are connected via the malate/aspartate and the glycerol-3-
phosphate shuttles [73]. Adequate NAD+ homeostasis is maintained in
nuclear/cytosolic and mitochondrial pools by autonomous NAD+
biosynthesis [72,73]. The peroxisomal NAD+ pool is possibly preserved
by the import of the NAD+ from the cytosol through the carrier protein.
Currently, the role of NAD+ in endoplasmic reticulum and golgi is not
well understood. Of the diﬀerent subcellular compartments, NAD+
concentration is highest in the mitochondrial compartment which
contains almost 70% of total cellular NAD+ [73]. However, this notion
needs to be conﬁrmed when future technical improvements will allow
us to measure NAD+ levels in diﬀerent cell compartments.
4.3. NAD+ biosynthesis
Intracellular NAD+ availability is controlled by biosynthesis of
NAD+, which can occur via de novo synthesis from the dietary
derived amino acid tryptophan or salvage pathways (Fig. 2A). As
enzymes involved in the de novo synthesis pathway are not well
expressed in adipose tissue [74], this pathway most likely has a
negligible role in NAD+ biosynthesis in adipose tissue in mammals.
Thus, the majority of the NAD+ in adipose tissue is synthesized via
salvage pathways, which require the uptake of NAD+ precursors
from the diet [74]. Forms of the dietary vitamin B3, niacin (NA),
nicotinamide (NAM) and nicotinamide riboside (NR), can serve as
the NAD+ precursor in the salvage pathways (Fig. 2A).
Unfortunately, the preference for the NAD+ precursor use in WAT
and BAT has not yet been properly investigated. As BAT is more
metabolically active than WAT, BAT is likely to possess higher
capacity for NAD+ biosynthesis than WAT. This notion is supported
by the ﬁnding that expression of the key enzymes involved in the
salvage pathways is higher in BAT versus WAT [75].
The NAD+ precursor NAM can be derived from the diet but it is
also the end product of several intracellular NAD+ degradation
reactions (see next Section 4.4). WAT and BAT most likely recycle
and use intracellularly produced NAM readily for NAD+ synthesis. In
the cytosol, NAM is ﬁrst converted to NAM mononucleotide (NMN)
by the rate-limiting enzyme, NAM phosphoribosyltransferase
(NAMPT) (also known as visfatin) (Fig. 2A). Interestingly, in
addition to an intracellular form of NAMPT, an extracellular
circulating form [76] secreted from both WAT and BAT exists, but
the function of this extracellular form is still unclear. However, it has
been suggested to maintain normal NAD+ levels in hypothalamus
[70] and regulate insulin secretion in pancreas [76]. After the rate-
limiting NAMPT step, NMN is converted to NAD+ by NMN adeny-
lyltransferases (NMNATs) (Fig. 2A). There are three NMNAT iso-
forms (NMNAT1-3) with diﬀerent subcellular distributions in mam-
malian adipose tissue. NMNAT1 is mainly a nuclear enzyme, while
NMNAT2 is localized to the golgi complex and cytosol, and NMNAT3
is found in cytosol and mitochondria. Thus, these diﬀerent NMNAT
isoforms are most likely responsible for modulating cell compart-
ment-speciﬁc NAD+ pools.
Adipose tissue seems to also utilize NR as a precursor for NAD+
biosynthesis [71]. After entering the cell via equilibrative nucleoside
transporters, NR is converted to NMN in the cytosol by the rate-
limiting enzyme, NR kinase 1 (NRK1) (Fig. 2A) [75]. The subsequent
conversion of NMN to NAD+ is catalyzed by NMNATs (Fig. 2A). NRK1
gene and protein expression is higher in BAT by comparison to WAT
suggesting that NR is more readily metabolized in BAT [75]. This
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Fig. 2. Cellular NAD+ biosynthesis and consumption processes. (A) NAD+ can be synthesized de novo from the amino acid tryptophan and through the salvage pathway from
nicotinamide (NAM) or nicotinamide riboside (NR) or niacin (NA). (B) The competition of SIRTs and PARPs for the same intracellular NAD+ pool in the cell. In addition, eﬀect of
physiological stimuli on cellular NAD+ biosynthesis via nicotinamide phosphoribosyltransferase (NAMPT) and the activities of sirtuins (SIRTs) and poly(ADP-ribose) polymerases
(PARPs). AMPK; AMP-activated protein kinase, NRK; nicotinamide riboside kinase, NMNAT; nicotinamide mononucleotide adenylyltransferase, NAPRT; niacin phosphoribosyl-
transferase and ROS; reactive oxygen species.
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notion is supported by the ﬁnding that NR supplementation increased
intracellular NAD+ more eﬃciently in BAT than WAT in wild-type mice
[71]. The other isoform of NRK enzyme, NRK2, is not expressed in
WAT or BAT [75].
The third NAD+ precursor, NA, can be converted to NAD+ inside
the cell via the Preiss-Handler pathway in adipose tissue [74] (Fig. 2A).
NA is initially metabolized to form NA mononucleotide (NAMN) in the
reaction catalyzed by NA phosphoribosyltransferase (NAPRT)
(Fig. 2A). This is followed by the conversion of NAMN to NA adenine
dinucleotide (NAAD) by NMNATs. In the ﬁnal step in this pathway
NAAD is amidated to form NAD+ by the NAD synthase in an ATP-
dependent manner (Fig. 2A).
4.4. NAD+ consumers SIRTs and PARPS
The intracellular NAD+ levels are also inﬂuenced via the action of
several NAD+ consumer families such as SIRTs, PARPs and the
NAD+ glycohydrolases CD38 and CD157 [77]. All these enzymes
cleave NAD+ to produce diﬀerent ADP-ribosyl products and NAM.
However, in this review we focus on two most studied enzyme
families: SIRTs and PARPs, which are critical regulators of several
distinct cellular processes, such as DNA repair, inﬂammation, and
diﬀerentiation but also have an important role in mitochondrial
metabolism with opposing functions.
SIRTs are regulators that aﬀect their target proteins activities
through protein post-translational modiﬁcations such as deacetylation
[14]. The most of the SIRTs transfer an acetyl group from their target
proteins to ADP-ribose moiety of NAD+ to form 2-O-acetyl-ADP-ribose
and NAM (Fig. 2B) [14]. The family comprises of seven proteins
(SIRT1–SIRT7), which vary in tissue speciﬁcity, subcellular localiza-
tion, enzymatic activities and targets. Importantly, SIRTs and espe-
cially SIRT1, the most-studied SIRT family member, play an important
role in the regulation of metabolic health by activating mitochondrial
biogenesis and function.
PARPs, the enzyme family of up to 17 members, constitute the
major NAD+ consuming activity in the cell [78]. PARP1 is considered
to be the isoform responsible for the main PARP activity (85–90%)
in the cell while PARP2 accounts for the remaining PARP activity.
PARP1 and PARP2 are ubiquitously expressed in mammalian tissues
and mainly localized in nucleus. PARPs catalyze the reaction in
which ADP-ribose moiety from NAD+ is transferred to form
branched poly(ADP-ribose) polymers on their target proteins and
as a side-product NAM is generated (Fig. 2B) [79]. PARPs have an
opposing eﬀect of mitochondrial function than SIRT1. Deletion of
Parp1 or pharmacological PARP inhibition improve mitochondrial
function in mice [80,81].
It has been suggested that SIRT1 and PARP1 can interact and
subsequently inﬂuence each other's enzyme activities because they
compete for the same intracellular NAD+ pool (Fig. 2B) [78].
However, as the Km of PARP1 for NAD
+ is many fold lower than
intracellular NAD+ levels, SIRT1 activity is unlikely to reduce NAD+
content to the level limiting for PARP1 activity. Instead, SIRT1 can
reduce PARP1 activity via deacetylation of PARP1 [82]. In contrast
to PARP1, the Km of SIRT1 for NAD
+ is within the physiological
range of intracellular NAD+ concentrations. Therefore, SIRT1 activ-
ity is critically aﬀected by changes in NAD+ levels and PARP1 may be
able to dampen SIRT1 activity as its activation can deplete intracel-
lular NAD+ pools even by 80–90% [74]. In support of this notion,
genetic deletion of Parp1 or pharmacological PARP inhibition
increase intracellular NAD+ levels and activates SIRT1 in muscle
and BAT in mice [80,81]. It has been also suggested that PARP1
might inhibit SIRT1 via PARylation but this type of cross-modiﬁca-
tion has not been observed at least in myotubes [80]. Overall, the
SIRT1-PARP1 interaction seems to exist in muscle and BAT but
needs to be studied in more detail in adipose tissue.
4.5. The eﬀect of physiological conditions and obesity on NAD+
biosynthesis and consumption in adipose tissue
Intracellular NAD+ levels ﬂuctuate through the day in response to
various physiological stimuli but normally not more than 2-fold [74].
The regulation of the rate-liming enzyme for conversion of NAM,
NAMPT, is the best studied and understood. Gene and protein
expression of NAMPT shows diurnal oscillation regulated by a core
clock machinery in WAT in mice [83]. In addition, gene and protein
expression of NAMPT can be increased by physiological conditions that
activate AMP-activated protein kinase (AMPK) (Fig. 2B). For example,
exercise, caloric restriction and weight-loss have been shown to
increase expression of NAMPT in WAT (Fig. 2B) [69,84–86]. In
contrast, obesity, high-fat feeding and aging decrease NAMPT in
WAT (Fig. 2B) [43,66–68,87]. The regulation of BAT NAMPT is
currently poorly understood.
The NAD+ consumers, SIRTs and PARPs, respond to similar type of
physiological and stress conditions. Energy shortage, such as caloric
restriction, starvation and exercise, activate SIRTs due to an increase in
NAD+ availability (Fig. 2B). In contrast, aging and high-fat feeding
blunt SIRT activity by decreasing NAD+ biosynthesis (Fig. 2B). High-
fat feeding, obesity, aging, oxidative stress and DNA damage stimulate
PARPs while fasting suppresses PARP enzymes in peripheral tissues
(Fig. 2B) [80,88]. Moreover, long-term calorie restriction was demon-
strated to lower PARP activity in subcutaneous WAT in obese subjects
(Fig. 2B) [69]. The observation that obesity is characterized with low
adipose tissue NAD+ levels [43,66–68,87] has raised an important
question: what are the factors diminishing NAD+ levels in adipose
tissue in obesity? One likely factor is that energy or fat excess, such as
HFD-feeding, disturbs WAT NAMPT expression (Fig. 2B) [43,66–
68,87] and stimulates PARP activity (Fig. 2B) [80]. Inﬂammation and
oxidative stress may also reduce Nampt expression [67] and activate
PARPs [88], but whether this occurs in adipose tissue has not been
investigated. Sedentary life-style may also impair NAD+ biosynthesis as
evidence supports the role of exercise in the maintenance of adequate
NAD+ homeostasis in adipose tissue [84]. Collectively, deteriorated
NAD+ homeostasis in obesity is likely to reﬂect poor life-style and
dietary habits as well as adipose tissue stress condition.
4.6. Strategies to boost adipose tissue NAD+ levels and SIRT1 in
obesity
Recent animal studies have demonstrated that NAD+ restoration
therapy is a promising approach to activate SIRT1 [67,71]. As SIRT1
activation has been shown to protect against diet-induced weight and
fat gain during HFD [71,89,90], NAD+ restoration therapy has recently
emerged as a potential treatment option for obesity [71,89,90]. Cellular
NAD+ levels can be restored by stimulating NAD+ biosynthesis or by
inhibiting the activity of NAD+ consuming enzymes. Currently, the
most commonly tested approach has been the stimulation of NAD+
biosynthesis, which can be achieved either via treatment with pharma-
cological compounds that induce NAD+ biosynthesis enzymes or diet-
ary supplementation of NAD+ precursors, vitamin B3 forms, 5′ AMP-
activated protein kinase activators such as resveratrol, AICAR and
metformin have been established to increase mRNA and protein
expression of NAMPT in several tissues (Fig. 2B) [18]. However,
metformin is the only 5′ AMP-activated protein kinase activator
demonstrated to stimulate Nampt gene expression in adipose tissue
so far [87]. PPARα, PPARγ and PPARδ agonists may also provide a tool
to stimulate WAT Nampt expression [91,92]. Recently, the therapeutic
possibilities of NAD+ precursors, have been widely investigated in
diﬀerent disease models. NR and the NAD+ intermediate generated
from NR or NAM, NMN (Fig. 2B), have been observed to eﬃciently
boost intracellular NAD+ levels in BAT [71,75] and WAT [67,93],
respectively, in mice (Fig. 2B). NA and NAM are known to robustly
increase intracellular NAD+ levels in liver [14], but unfortunately their
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eﬀect on adipose tissue NAD+ levels have not been examined. NAD+
precursors are well-tolerated and not associated with severe side-
eﬀects. However, NA is known to cause cutaneous ﬂushing via
GPR109A receptor-activation mediated vasodilatation [94]. As NR
and NMN do not activate GPR109A receptor [71], their use in the
tissue NAD+ restoration therapy is nowadays preferred over NA. Both
of these vitamin B3 metabolites, as water-soluble compounds are
probably safe and cost-eﬀective potential therapy options. However,
long-term data in humans are still mostly lacking.
An attractive NAD+ restoration therapy approach is also the
inhibition of main NAD+ consuming enzymes PARPs (Fig. 2B).
Deﬁciency of Parp1 and Parp2 can cause an enormous rise in tissue
NAD+ levels in BAT and muscle [13,80,95]. Development of pharma-
cological pan-PARP [88] inhibitors have opened new avenues for
targeting NAD+ consuming enzymes. As expected, PARP inhibitors
have been shown to elevate NAD+ levels in multiple tissues such as
muscle and liver [81,96,97], but adipose tissue has not been investi-
gated in these studies. Furthermore, there are no human studies in
which the eﬀect of PARP inhibitor treatment on tissue NAD+ levels has
been investigated. Thus, further work is required to evaluate the
eﬃcacy of PARP inhibitors on adipose tissue NAD+ levels in mice
and humans. It is also of interest to develop speciﬁc PARP1 inhibitors
since Parp2 deletion leads to glucose intolerance due to failure of
pancreatic function in mice [13]. As PARP1 is involved in DNA repair,
further studies are also needed to ensure the safety of chronic
inhibition of this enzyme. However, long-term treatment with pan-
PARP inhibitor was not observed to cause DNA damage in treated mice
[81].
In spite of above mentioned pharmacological approaches, the most
cost-eﬀective therapy options to replenish the adipose tissue NAD+
levels in obesity are diet-induced weight-loss and exercise, as they are
known to activate NAMPT in WAT [69,84] and attenuate PARP
activation in subcutaneous WAT in obese subjects (Fig. 2B) [69].
Notably, lifestyle modiﬁcations combined with the vitamin B3 nutri-
tional therapies could be a powerful approach to improve NAD+
metabolism. Several ongoing human clinical trials with NAD+ pre-
cursors will reveal their eﬃcacy in humans in the near future.
5. SIRTs and PARPs in adipose tissue function in basal and
obese conditions
5.1. Introduction
The role of NAD+-dependent SIRTs and PARPs in the regulation of
metabolic and mitochondrial functions has been mostly investigated in
tissues considered to be metabolically active, such as muscle and liver,
but less is known about their function in adipose tissue and obesity. In
the following section we aim to review what is known about these two
families in regard to the central functions of WAT and BAT. We provide
an update on the physiological actions of SIRTs and PARPs in adipose
tissue based on the lessons learned from mouse and human studies
(Table 1).
5.2. Expression of SIRTs and PARPs in WAT in basal and obese
conditions
Studies in both rodent models and humans have shown that all
SIRT genes are expressed in WAT and regulated by obesity (Fig. 3). In
rodents, HFD induced obesity decreases the WAT expression level of
Sirt1-4 and Sirt6, whereas acute HFD increases the WAT expression of
Sirt5 [40,98–102]. In contrast, caloric restriction increases Sirt1 and
Sirt2 but reduces Sirt4mRNA and protein level in WAT [85,103–105].
Human studies have similarly shown that SIRT1 is expressed in both
subcutaneous and visceral WAT and reduced by obesity [43,69,106–
110]. The expressions of SIRT2, SIRT3 and SIRT5 were reported to be
either reduced [43,69,102], or unaﬀected in obese subcutaneous WAT
[108]. For SIRT7 results between diﬀerent studies have also been
varied: Rappou and colleagues [69] found decreased expression in
obese subcutaneous WAT, whereas no expression diﬀerence [43] or
increased expression [108] has also been reported. Caloric restriction
and weight loss induced by gastric band operation increased the
expression of SIRT1, SIRT3 and SIRT6 in subcutaneous WAT in obese
subjects [111], whereas long-term weight loss based on conventional
caloric restriction diet regiment increased the mRNA levels of SIRT1
and SIRT7, but in contrast to gastric banding, SIRT3 expression was
further reduced [69].
PARP expression has been less studied in WAT. Thus, we examined
the mRNA expression of all 17 PARP family members from microarray
data of the lean, metabolically healthy twin of BMI discordant
monozygotic twins from our earlier publication [43] to elucidate
WAT expression of PARP family genes. Expression of 13 out of 17
PARP gene family members was detected in human WAT, with the
expression level of PARP1 being the highest (Supplemental Fig. 1).
Recent human studies showed that total PARP activity is elevated in
obesity and is reduced by weight loss (Fig. 3) [43,69].
5.3. The function of SIRTs and PARPs in WAT
5.3.1. Adipogenesis
Adipose tissue is renewed by recruitment of mesenchymal stem
cells to diﬀerentiation into adipocytes, adipogenesis. Adipogenesis is
orchestrated by transcriptional program where the master regulator is
Pparγ that works in concert with other transcriptional regulators, most
notably the CAAT enhancer binding proteins transcription factor
family to promote adipocyte diﬀerentiation (Fig. 1A) [112].
Interestingly, activation of mitochondrial biogenesis program and an
increase of mitochondrial mass and oxidative capacity characterize
adipocyte diﬀerentiation, highlighting the importance of mitochondrial
function for adipocytes [113].
Studies with the mouse 3T3-L1 cell line capable of diﬀerentiating
into adipocytes have shown that Sirt1 inhibits adipogenesis (Fig. 3).
Overexpression of Sirt1 reduces gene expression of the adipogenic
transcriptional program and markers of terminal diﬀerentiation,
whereas Sirt1 knock-down has the opposite eﬀect [114].
Mechanistically Sirt1 interacts with Pparγ and its co-repressors,
suggesting that Sirt1 impairs adipogenesis through inhibiting Pparγ
signaling by docking with these co-repressors [114]. In vivo data
conﬁrm Sirt1 as a negative regulator of adipogenesis. Adipocyte-
speciﬁc Sirt1 deletion increased the adipogenic capacity of WAT in
mice in response to chronic HFD as demonstrated by white adipocyte
hyperplasia and hyperacetylation mediated activation of Pparγ [115],
and increased WAT mass [101,115] even under normal conditions. In
agreement, mouse embryonic ﬁbroblasts derived from mice homo- or
heterozygous for Sirt1 deletion, were shown to possess higher adipo-
genic capacity in cell culture [116,117]. By contrast, treatment with
pharmacological SIRT1 activators decreases WAT mass during HFD
[71,89,90]. Bone marrow derived mesenchymal stem cells with Sirt1
deletion have a serious defect in self-renewal and osteoblast diﬀer-
entiation, while adipocyte diﬀerentiation was only modestly aﬀected
but adipocytes were smaller containing less lipids [118]. Taken
together these results demonstrate that while Sirt1 inhibits adipocyte
diﬀerentiation, it is required for maintenance of the mesenchymal stem
cell pool and sustained renewal of WAT in vivo.
Based on studies in cultured adipocytes Sirt2 has a similar
inhibitory eﬀect on adipogenesis as Sirt1; overexpression of Sirt2
inhibits adipogenesis whereas Sirt2 inhibition promotes it (Fig. 3). The
underlying mechanism is suggested to be Sirt2 mediated deacetylation
of forkhead box protein O1, which binds and represses Pparγ after
nuclear localization (Fig. 3) [105,119]. However, the eﬀect of Sirt2 on
adipogenesis has not yet been investigated in vivo.
In contrast to Sirt1 and Sirt2, Sirt7 appears to be a positive
regulator of adipogenesis (Fig. 3) [120]. Gene expression level of the
R. Jokinen et al. Redox Biology 12 (2017) 246–263
253
T
a
b
le
1
A
n
im
al
m
od
el
s
an
d
h
u
m
an
st
u
d
ie
s
of
SI
R
T
s
an
d
P
A
R
P
s
in
W
A
T
an
d
B
A
T
.
St
u
d
y
m
od
el
In
te
rv
en
ti
on
(l
en
gt
h
)
O
ve
ra
ll
m
et
ab
ol
ic
p
h
en
ot
yp
e
W
A
T
p
h
en
ot
yp
e
B
A
T
p
h
en
ot
yp
e
R
ef
er
en
ce
R
o
d
e
n
ts
A
d
ip
os
e
ti
ss
u
e-
sp
ec
iﬁ
c
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
↑
SA
T
an
d
V
A
T
m
as
s
↑
M
as
s
↑
d
u
e
to
in
cr
ea
se
d
ad
ip
os
it
y
[1
01
]
SI
R
T
1
K
O
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↓
L
ar
ge
ad
ip
oc
yt
es
w
it
h
en
la
rg
ed
li
p
id
d
ro
p
le
ts
F
A
B
P
4
p
ro
m
ot
er
P
la
sm
a
le
p
ti
n
↑,
ad
ip
on
ec
ti
n
-
C
57
B
L
/6
H
F
D
(8
–
12
w
ee
ks
)
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↓
P
la
sm
a
le
p
ti
n
↑,
ad
ip
on
ec
ti
n
↓
M
as
s
↑
A
d
ip
os
e
ti
ss
u
e-
sp
ec
iﬁ
c
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
↑
W
A
T
m
as
s
↑
M
as
s
↑
d
u
e
to
in
cr
ea
se
d
ad
ip
os
it
y
SI
R
T
1
K
O
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↓
[1
07
,1
15
]
aP
2
p
ro
m
ot
er
C
57
B
L
/6
H
F
D
(5
w
ee
ks
)
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↓
L
ar
ge
ad
ip
oc
yt
es
M
as
s
↑
In
fl
am
m
at
io
n
↑
H
F
D
(1
5
w
ee
ks
)
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↑
Sm
al
l
ad
ip
oc
yt
es
,
h
yp
er
p
la
si
a
M
as
s
↑
In
fl
am
m
at
io
n
↓
T
h
er
m
og
en
ic
ge
n
es
↑
P
P
A
R
g
si
gn
al
in
g
↑
SI
R
T
1
K
O
R
eg
u
la
r
d
ie
t
P
os
tn
at
al
le
th
al
,
sm
al
l
in
si
ze
T
h
er
m
og
en
ic
ge
n
es
↓
T
h
er
m
og
en
ic
ge
n
es
n
ot
ch
an
ge
d
[1
48
]
H
om
oz
yg
ot
e
O
n
ly
sm
al
l
fr
ac
ti
on
of
m
ic
e
su
rv
iv
e
to
ad
u
lt
h
oo
d
12
9/
J×
C
57
B
L
/6
J
SI
R
T
1
K
O
R
eg
u
la
r
d
ie
t
O
ve
ra
ll
m
et
ab
ol
is
m
n
or
m
al
P
h
en
ot
yp
e
n
ot
ch
an
ge
d
P
h
en
ot
yp
e
n
ot
ch
an
ge
d
[1
34
,1
38
]
H
et
er
oz
yg
ot
e
C
57
B
L
/6
M
ed
iu
m
/h
ig
h
-f
at
d
ie
t
(1
2
–
16
w
ee
ks
)
B
od
y
w
ei
gh
t
↑
E
n
er
gy
ex
p
en
d
it
u
re
↓
SA
T
m
as
s
↑
In
fl
am
m
at
io
n
↑
E
n
la
rg
ed
li
p
id
d
ro
p
le
ts
T
h
er
m
og
en
ic
re
sp
on
se
↓
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↓
E
xp
re
ss
io
n
of
le
p
ti
n
↓/
-
an
d
ad
ip
on
ec
ti
n
-
M
it
oc
h
on
d
ri
al
co
n
te
n
t
↓
L
iv
er
st
ea
to
si
s
↑
In
su
li
n
si
gn
al
in
g
↓
F
A
ox
id
at
io
n
↓
F
at
/l
iv
er
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
↓
W
A
T
m
as
s
↓
P
h
en
ot
yp
e
n
ot
re
p
or
te
d
[1
07
,1
56
]
SI
R
T
1
d
eﬁ
ci
en
cy
ra
t
F
oo
d
in
ta
ke
↓
P
la
sm
a
le
p
ti
n
↓,
ad
ip
on
ec
ti
n
↓
A
n
ti
se
n
se
ol
ig
on
u
cl
eo
ti
d
e
(A
SO
)
P
la
sm
a
ch
ol
es
te
ro
l
↓
an
d
F
A
↓
Sp
ra
gu
e-
D
aw
le
y
ra
ts
H
F
D
F
oo
d
in
ta
ke
↓
V
A
T
m
as
s
↓
In
fl
am
m
at
io
n
↑
D
bc
1
K
O
R
eg
u
la
r
d
ie
t
T
h
er
m
og
en
ic
re
sp
on
se
↑
u
p
on
co
ld
ex
p
os
u
re
P
h
en
ot
yp
e
n
ot
ch
an
ge
d
[1
48
]
SI
R
T
1
in
h
ib
it
or
C
57
B
L
/6
×
12
9/
J
A
d
ip
os
e
ti
ss
u
e-
sp
ec
iﬁ
c
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
↓
F
at
m
as
s
n
ot
ch
an
ge
d
P
h
en
ot
yp
e
n
ot
re
p
or
te
d
[1
26
]
H
um
an
SI
R
T
1
ov
er
ex
pr
es
si
on
E
n
er
gy
ex
p
en
d
it
u
re
↑
L
ip
ol
ys
is
↑
aP
2
p
ro
m
ot
er
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↑
E
xp
re
ss
io
n
of
an
d
p
la
sm
a
ad
ip
on
ec
ti
n
↑
C
57
B
L
/6
J
L
iv
er
an
d
m
u
sc
le
li
p
id
co
n
te
n
t
↓
L
ip
og
en
es
is
↓
SI
R
T
1
ov
er
ex
p
er
ss
io
n
R
eg
u
la
r
d
ie
t/
H
F
D
B
od
y
w
ei
gh
t
n
ot
ch
an
ge
d
/
co
m
p
ar
ab
le
w
ei
gh
t
ga
in
P
h
en
ot
yp
e
n
ot
ch
an
ge
d
L
ip
id
d
ro
p
le
t
si
ze
↓
[1
27
]
H
om
oz
yg
ot
e
E
n
er
gy
ex
p
en
d
it
u
re
↑
T
h
er
m
og
en
ic
re
sp
on
se
↑
C
57
B
L
/6
N
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↑
M
it
oc
h
on
d
ri
al
co
n
te
n
t
n
ot
ch
an
ge
d
F
A
ox
id
at
io
n
↑
SI
R
T
1
ov
er
ex
p
er
ss
io
n
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
↓
V
A
T
m
as
s
↓
P
h
en
ot
yp
e
n
ot
re
p
or
te
d
[1
40
]
B
et
a-
ac
ti
n
p
ro
m
ot
er
P
la
sm
a
F
A
an
d
ch
ol
es
te
ro
l
↓
P
la
sm
a
le
p
ti
n
↓,
ad
ip
on
ec
ti
n
↓
H
et
er
oz
yg
ot
es
E
n
er
gy
ex
p
en
d
it
u
re
↑
C
57
B
L
/6
×
12
9/
Sv
G
lu
co
se
to
le
ra
n
ce
↑
(c
on
ti
n
u
ed
on
n
ex
t
p
a
g
e)
R. Jokinen et al. Redox Biology 12 (2017) 246–263
254
T
a
b
le
1
(c
on
ti
n
u
ed
)
St
u
d
y
m
od
el
In
te
rv
en
ti
on
(l
en
gt
h
)
O
ve
ra
ll
m
et
ab
ol
ic
p
h
en
ot
yp
e
W
A
T
p
h
en
ot
yp
e
B
A
T
p
h
en
ot
yp
e
R
ef
er
en
ce
SI
R
T
1
ov
er
ex
p
er
ss
io
n
R
eg
u
la
r
d
ie
t
O
ve
ra
ll
m
et
ab
ol
is
m
n
or
m
al
P
h
en
ot
yp
e
n
ot
ch
an
ge
d
P
h
en
ot
yp
e
n
ot
ch
an
ge
d
[1
54
]
H
et
er
oz
yg
ot
e
C
57
B
L
/6
H
F
D
(1
9
w
ee
ks
)
E
n
er
gy
ex
p
en
d
it
u
re
↑
F
at
m
as
s
n
ot
ch
an
ge
d
T
h
er
m
og
en
ic
re
sp
on
se
↓
G
lu
co
se
to
le
ra
n
ce
↑
P
ro
te
ct
ed
fr
om
li
ve
r
st
ea
to
si
s
SI
R
T
1
ov
er
ex
p
re
ss
io
n
R
eg
u
la
r
d
ie
t
E
n
er
gy
ex
p
en
d
it
u
re
↓
F
at
m
as
s
n
ot
ch
an
ge
d
P
h
en
ot
yp
e
n
ot
ch
an
ge
d
[1
07
,1
39
,1
48
]
H
et
er
oz
yg
ot
e
G
lu
co
se
/i
n
su
li
n
m
et
ab
ol
is
m
n
or
m
al
P
la
sm
a
ad
ip
on
ec
ti
n
↑
C
57
B
L
/6
J
T
h
er
m
og
en
ic
re
sp
on
se
↑
u
p
on
co
ld
ex
p
os
u
re
C
ro
ss
br
ed
w
it
h
d
b/
d
b
m
ic
e
C
om
p
ar
ab
le
w
ei
gh
t
ga
in
C
om
p
ar
ab
le
fa
t
ga
in
G
lu
co
se
to
le
ra
n
ce
↑
H
F
D
(6
–
16
w
ee
ks
)
C
om
p
ar
ab
le
w
ei
gh
t
ga
in
C
om
p
ar
ab
le
fa
t
ga
in
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↑
In
fl
am
m
at
io
n
↓
SI
R
T
3
K
O
F
as
ti
n
g
Im
p
ai
re
d
gl
u
co
se
m
et
ab
ol
is
m
u
p
on
co
ld
ex
p
os
u
re
P
h
en
ot
yp
e
n
ot
ch
an
ge
d
F
A
ox
id
at
io
n
↓
[1
42
,1
57
]
12
9/
Sv
C
ol
d
to
le
ra
n
ce
↓
SI
R
T
4
K
O
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
n
ot
ch
an
ge
d
L
ip
og
en
es
is
↑
[1
04
]
12
9/
J
O
ve
ra
ll
m
et
ab
ol
is
m
n
or
m
al
H
F
D
(1
6
w
ee
ks
)
W
ei
gh
t
ga
in
↓
W
A
T
ga
in
↓
M
as
s
n
ot
ch
an
ge
d
E
n
er
gy
ex
p
en
d
it
u
re
↑
L
ip
og
en
es
is
↑
C
om
p
ar
ab
le
in
su
li
n
an
d
gl
u
co
se
to
le
ra
n
ce
SI
R
T
6
K
O
R
eg
u
la
r
d
ie
t
L
et
h
al
h
yp
og
ly
ce
m
ia
SA
T
m
as
s
↓
G
lu
co
se
u
p
ta
ke
↑
[1
55
,1
58
]
12
9/
Sv
J
Sm
al
l
bo
d
y
si
ze
SI
R
T
6
ov
er
ex
p
re
ss
io
n
R
eg
u
la
r
d
ie
t
O
ve
ra
ll
m
et
ab
ol
is
m
n
or
m
al
F
at
m
as
s
n
ot
ch
an
ge
d
N
ot
re
p
or
te
d
[1
31
]
H
F
D
(1
6
w
ee
ks
)
C
om
p
ar
ab
le
w
ei
gh
t
ga
in
V
A
T
ga
in
↓
G
lu
co
se
to
le
ra
n
ce
↑
T
ri
gl
yc
er
id
e
sy
n
th
es
is
↓
P
la
sm
a
F
A
,
T
G
an
d
ch
ol
es
te
ro
l
↓
SI
R
T
7
K
O
H
F
D
(2
2
w
ee
ks
)
L
iv
er
st
ea
to
si
s
↓
W
A
T
m
as
s
↓
B
A
T
m
as
s
↓
[1
35
]
C
57
B
L
/6
J
G
lu
co
se
to
le
ra
n
ce
↑
P
la
sm
a
le
p
ti
n
↓
an
d
ad
ip
on
ec
ti
n
-
T
h
er
m
og
en
ic
re
sp
on
se
↑
In
fl
am
m
at
io
n
↓
P
A
R
P
1
K
O
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
↓
W
A
T
m
as
s
↓
T
h
er
m
og
en
ic
re
sp
on
se
↑
[1
3]
C
57
B
L
/6
E
n
er
gy
ex
p
en
d
it
u
re
↑
M
it
oc
h
on
d
ri
al
co
n
te
n
t
↑
P
la
sm
a
F
A
an
d
T
G
↓
F
A
ox
id
at
io
n
↑
G
lu
co
se
to
le
ra
n
ce
↑
H
F
D
(8
w
ee
ks
)
W
ei
gh
t
ga
in
↓
W
A
T
ga
in
↓
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↑
P
la
sm
a
F
A
↓
P
A
R
P
1
K
O
R
eg
u
la
r
d
ie
t
O
ve
ra
ll
m
et
ab
ol
is
m
n
or
m
al
P
h
en
ot
yp
e
u
n
af
fe
ct
ed
P
h
en
ot
yp
e
n
ot
re
p
or
te
d
[1
23
]
C
57
B
L
/6
H
F
D
(1
4
w
ee
ks
)
W
ei
gh
t
ga
in
↓
A
d
ip
oc
yt
e
si
ze
↓
L
iv
er
st
ea
to
si
s
↑
A
d
ip
og
en
es
is
↓
P
la
sm
a
F
A
,
T
G
an
d
ch
ol
es
te
ro
l
↑
In
fl
am
m
at
io
n
↓
G
lu
co
se
to
le
ra
n
ce
↓
P
A
R
P
1
K
O
R
eg
u
la
r
d
ie
t
O
ve
ra
ll
m
et
ab
ol
is
m
n
or
m
al
P
la
sm
a
le
p
ti
n
-
P
h
en
ot
yp
e
n
ot
re
p
or
te
d
[1
59
]
12
9/
Sv
Im
J
H
F
D
(1
9
w
ee
ks
)
W
ei
gh
t
ga
in
↑
W
A
T
m
as
s
↑
L
ip
id
co
n
te
n
t
↑
E
n
er
gy
ex
p
en
d
it
u
re
↓
A
d
ip
oc
yt
e
si
ze
↑
T
h
er
m
og
en
ic
re
sp
on
se
↓
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↓
P
la
sm
a
le
p
ti
n
↑
(c
on
ti
n
u
ed
on
n
ex
t
p
a
g
e)
R. Jokinen et al. Redox Biology 12 (2017) 246–263
255
T
a
b
le
1
(c
on
ti
n
u
ed
)
St
u
d
y
m
od
el
In
te
rv
en
ti
on
(l
en
gt
h
)
O
ve
ra
ll
m
et
ab
ol
ic
p
h
en
ot
yp
e
W
A
T
p
h
en
ot
yp
e
B
A
T
p
h
en
ot
yp
e
R
ef
er
en
ce
P
A
R
P
2
K
O
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
↓
W
A
T
m
as
s
↓
P
h
en
ot
yp
e
n
ot
ch
an
ge
d
[1
3,
12
5]
C
57
B
L
/6
J×
SV
12
9
E
n
er
gy
ex
p
en
d
it
u
re
↑
A
d
ip
oc
yt
e
si
ze
↓
A
d
ip
og
en
es
is
↓
In
fl
am
m
at
io
n
↑
H
F
D
(8
w
ee
ks
)
W
ei
gh
t
ga
in
↓
W
A
T
m
as
s
↓
E
n
er
gy
ex
p
en
d
it
u
re
↑
In
fl
am
m
at
io
n
↑
In
su
li
n
se
n
si
ti
vi
ty
↑
G
lu
co
se
in
to
le
ra
n
t
d
u
e
to
be
ta
-c
el
l
d
ys
fu
n
ct
io
n
SI
R
T
1
ac
ti
va
to
r
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
u
n
af
fe
ct
ed
[9
0]
R
es
ve
ra
tr
ol
C
57
B
L
/6
H
F
D
(1
5
w
ee
ks
)
W
ei
gh
t
ga
in
↓
W
A
T
ga
in
↓
L
ip
id
d
ro
p
le
t
si
ze
↓
E
n
er
gy
ex
p
en
d
it
u
re
↑
A
d
ip
oc
yt
e
si
ze
↓
T
h
er
m
og
en
ic
re
sp
on
se
↑
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↑
M
it
oc
h
on
d
ri
al
co
n
te
n
t
↑
SI
R
T
1
ac
ti
va
to
r
SR
T
17
20
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
u
n
af
fe
ct
ed
[8
9]
C
57
B
L
/6
G
lu
co
se
to
le
ra
n
ce
↑
P
la
sm
a
T
G
↓
H
F
D
(1
3–
20
w
ee
ks
)
W
ei
gh
t
ga
in
↓
W
A
T
ga
in
↓
L
ip
id
d
ro
p
le
t
si
ze
↓
E
n
er
gy
ex
p
en
d
it
u
re
↑
A
d
ip
oc
yt
e
si
ze
↓
E
xp
re
ss
io
n
of
U
C
P
1
u
n
af
fe
ct
ed
,
U
C
P
3
↑
In
su
li
n
se
n
si
ti
vi
ty
an
d
gl
u
co
se
to
le
ra
n
ce
↑
F
A
ox
id
at
io
n
↑
P
la
sm
a
T
G
an
d
ch
ol
es
te
ro
l
↓
L
iv
er
st
ea
to
si
s
↓
N
A
D
+
p
re
cu
rs
or
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
u
n
af
fe
ct
ed
SI
R
T
1
an
d
SI
R
T
3
n
ot
ac
ti
va
te
d
SI
R
T
1
an
d
SI
R
T
3
ac
ti
va
te
d
[7
1]
N
ic
ot
in
am
id
e
ri
bo
si
d
e
In
su
li
n
se
n
si
ti
vi
ty
↑
C
ol
d
to
le
ra
n
ce
↑
C
57
B
L
/6
H
F
D
(8
–
16
w
ee
ks
)
W
ei
gh
t
ga
in
↓
V
A
T
m
as
s
↓
C
ol
d
to
le
ra
n
ce
↑
E
n
er
gy
ex
p
en
d
it
u
re
↑
M
it
oc
h
on
d
ri
al
co
n
te
n
t
↑
P
an
-P
A
R
P
in
h
ib
it
or
R
eg
u
la
r
d
ie
t
B
od
y
w
ei
gh
t
u
n
af
fe
ct
ed
W
A
T
m
as
s
u
n
af
fe
ct
ed
M
as
s
u
n
af
fe
ct
ed
[8
1,
12
4]
M
R
L
B
-4
56
96
C
57
B
L
/6
H
F
D
(1
8
w
ee
ks
)
W
ei
gh
t
ga
in
↓
SA
T
ga
in
↓
M
as
s
u
n
af
fe
ct
ed
E
n
er
gy
ex
p
en
d
it
u
re
↑
A
d
ip
oc
yt
e
si
ze
↓
E
xp
re
ss
io
n
of
ad
ip
on
ec
ti
n
↓
In
fl
am
m
at
io
n
↓
H
u
m
a
n
s
O
be
se
B
as
al
co
n
d
it
io
n
M
ix
ed
gr
ou
p
of
su
bj
ec
ts
w
it
h
/
w
it
h
ou
t
m
et
ab
ol
ic
sy
n
d
ro
m
e
SI
R
T
1
ex
p
re
ss
io
n
↓
[1
08
]
SI
R
T
2-
SI
R
T
6
ex
p
re
ss
io
n
u
n
af
fe
ct
ed
SI
R
T
7
ex
p
re
ss
io
n
↑
O
be
se
B
as
al
co
n
d
it
io
n
C
li
n
ic
al
ly
h
ea
lt
h
y
SI
R
T
1/
SI
R
T
3/
SI
R
T
7
ex
p
re
ss
io
n
↓
[6
9]
P
A
R
P
ac
ti
vi
ty
↑
C
or
re
la
ti
on
(+
):
P
A
R
P
ac
ti
vi
ty
an
d
W
A
T
m
as
s
C
or
re
la
ti
on
(-
):
SI
R
T
1
ex
p
re
ss
io
n
an
d
in
fl
am
m
at
io
n
C
or
re
la
ti
on
(+
):
SI
R
T
1
an
d
in
su
li
n
se
n
si
ti
vi
ty
C
al
or
ic
re
st
ri
ct
io
n
d
ie
t
SI
R
T
1/
SI
R
T
7
ex
p
re
ss
io
n
↑
SI
R
T
3
ex
p
re
ss
io
n
↓
P
A
R
P
ac
ti
vi
ty
↓
O
be
se
B
as
al
co
n
d
it
io
n
M
et
ab
ol
ic
sy
n
d
ro
m
e
n
ot
re
p
or
te
d
SI
R
T
1
ex
p
re
ss
io
n
↓
[1
07
]
C
or
re
la
ti
on
(-
):
SI
R
T
1
ex
p
re
ss
io
n
an
d
in
fl
am
m
at
io
n
(c
on
ti
n
u
ed
on
n
ex
t
p
a
g
e)
R. Jokinen et al. Redox Biology 12 (2017) 246–263
256
adipogenic transcriptional program in WAT from mice homozygous for
Sirt7 deletion was reduced, and freshly isolated early adipogenic
precursor cells were diminished in number and had impaired adipo-
genic capacity in culture. Furthermore SIRT7 knockdown in primary
human preadipocytes impaired lipid accumulation and decreased the
number of cells that expressed the terminal adipocyte diﬀerentiation
marker fatty acid-binding protein 4 [120]. It has been proposed that
the opposite eﬀects of Sirt1 and Sirt7 on adipogenesis could be
mediated by direct inhibition of Sirt1 by Sirt7 [121]. However, SIRT7
has been reported to either behave similarly to SIRT1 and be down-
regulated [69], or in an opposite manner and be upregulated [108] in
obese by comparison to lean subjects in humans. Thus, further
research is required to clarify whether SIRT7 truly has opposing eﬀects
on adipogenesis as SIRT1.
Parp1 and Parp2 have been shown to promote adipogenesis in cell
lines and in vivo (Fig. 3). Parp activity increases during adipogenesis
and lentiviral Parp1 knockdown or Parp inhibition in 3T3-L1 cells
impairs adipogenic diﬀerentiation through reduced gene expression of
Pparγ and Pparγ responsive adipogenic genes [122]. Parp1 deletion in
mice leads to morphologically abnormal WAT with small adipocytes
upon HFD and preadipocytes isolated from these mice exhibit impaired
capacity for adipogenic diﬀerentiation in culture [123]. In agreement,
Parp inhibition during HFD leads to small adipocyte morphology
similar to Parp1 deletion in mice and is associated with reduced gene
expression level of Pparγ target genes in WAT [124]. Mechanistically
Parp1 was shown to associate with Pparγ responsive promoters and
enhance Pparγ ligand binding, which mediates co-activator and co-
repressor exchange in a poly(ADP-ribosyl)ation dependent manner
(Fig. 1A) [124]. Similarly to Parp1, Parp2 deletion in mice resulted in
small and irregular adipocyte morphology and reduced gene expression
Pparγ target genes, even under unchallenged conditions [125]. In
agreement, diﬀerentiation of mouse embryonic ﬁbroblasts with Parp2
deletion into adipocytes was impaired in culture [125]. Mechanistically
Parp2 seems to directly interact with Pparγ on the chromatin and
increase Pparγ-driven gene expression. In humans, the eﬀect of PARPs
on adipogenesis has not yet been studied. However, recent study
demonstrated that WAT PARP activity correlates positively with fat
mass in humans [69], which may in part reﬂect the capability of PARPs
to promote adipogenic capacity.
5.3.2. Lipid homeostasis
WAT lipid homeostasis is determined by lipid synthesis, storage
and utilization through lipolysis and mitochondrial fatty acid β-
oxidation. Based on current evidence SIRTs regulate lipid homeostasis
in WAT, but to our knowledge the role of PARPs has not been
investigated.
The majority of in vitro and vivo data indicate that Sirt1 regulates
adipocyte lipolysis (Fig. 3). Pharmacological Sirt1 activation increased
lipolysis and fatty acid release from rodent adipocytes in culture under
basal and β-adrenergic stimulated conditions, whereas Sirt1 inhibition
had the opposite eﬀect [114]. In agreement, heterozygous loss of Sirt1
decreases plasma free fatty acid concentrations in mice through a
reduction of β-adrenergic mediated fatty acid release from adipocytes
[114]. Adipocyte speciﬁc overexpression of human SIRT1 in mice
increases basal lipolytic rate and the expression level of adipose
triglyceride lipase, a key enzyme in the lipolytic pathway [126].
However, in another Sirt1 overexpression model, WAT lipolysis rate
was unaﬀected [127]. Mechanistic studies in cultured adipocytes have
indicated that Sirt1 promotes lipolysis via deacetylation and activation
of forkhead box protein O1, which in turn stimulates the expression of
adipose triglyceride lipase [128]. SIRT1 may also have an eﬀect on
adipocyte fatty acid β-oxidation as a trend for increased WAT fatty acid
β-oxidation was observed in SIRT1 overexpressing mice (Fig. 3), but
these results did not reach statistical signiﬁcance [126]. Similar to
Sirt1, Sirt2 overexpression also promoted basal and insulin stimulated
lipolysis [105] and increased fatty acid oxidation in 3T3-L1 diﬀeren-Ta
b
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tiated adipocytes, while Sirt2 knock down impaired fatty acid oxidation
(Fig. 3) [102]. Further research is required to investigate the role of
Sirt2 in WAT lipolysis and fat oxidation in vivo.
SIRTs are also involved in the regulation of lipogenesis in mouse
WAT. Genetic or pharmacological Sirt1 activation reduces the rate-
limiting enzyme in de novo lipogenesis, acetyl-CoA carboxylase, and
expression of genes in the lipogenic pathway in mice or a human
preadipocyte line, respectively [126,129]. Therefore, based on these
studies, Sirt1 appears to inhibit lipogenesis in WAT (Fig. 3). In
contrast, deletion of the mitochondrial Sirt4 decreased lipogenesis in
freshly isolated adipocytes and WAT (Fig. 3) [104]. This ﬁnding can be
explained by the dual role of Sirt4 in the regulation of fat catabolism
and anabolism. In fed state Sirt4 promotes lipid synthesis by deacety-
lating and inactivating the malonyl-CoA decarboxylase, which increases
the amount of malonyl-CoA, the metabolite that represses lipid
oxidation [130]. During fasting WAT Sirt4 expression reduces leading
to an activation of malonyl-CoA carboxylase and lipid oxidation. Sirt6
has also been implicated in the control of lipogenesis. Sirt6may act as a
negative regulator of lipid triglyceride synthesis based on transcrip-
tional changes in WAT of Sirt6 overexpressing mice during HFD
(Fig. 3). Notably, the expression levels of Pparγ responsive lipid
metabolism genes and diacylglycerol acyltransferases, key enzymes in
triglyceride synthesis, were signiﬁcantly downregulated in the Sirt6
overexpressing mice in comparison with controls [131].
5.3.3. OXPHOS
SIRTs are described as regulators of mitochondrial respiration and
oxidative metabolism in non-adipose tissues [14], but their role in WAT
respiration during basal conditions or obesity is poorly investigated.
Fasting has been shown to induce both Sirt1 expression and increase in
mitochondrial function assessed as mtDNA copy number, expression of
OXPHOS genes and mitochondrial respiration capacity in WAT [100].
Moreover, pharmacological activation of Sirt1 protects from HFD induced
obesity [71,89,90], which may in part be explained by upregulation of
genes involved in oxidative metabolism (such as PGC-1α) in WAT along
with non-adipose tissues and inhibition of adipogenesis [89]. In contrast,
Sirt1 overexpression in mice did not aﬀect mitochondrial respiration
capacity determined by high-resolution respirometry or OXPHOS
complex subunit protein amount in mouse WAT during unchallenged
conditions or caloric restriction [127,132]. However, it is worth noting
that the caloric restriction employed in this study, every other day feeding,
did not induce an increase in Sirt1 expression in WAT in wild type mice.
Therefore, further research is needed to clarify the role of SIRTs in
regulation of WAT mitochondrial respiration under basal conditions and
during metabolic challenges such as obesity or fasting. Studies examining
the role of PARPs on WAT respiration are at present lacking.
5.3.4. WAT inﬂammation and cytokine secretion
WAT inﬂammation is a key characteristic of obesity and is
considered to contribute to obesity related pathologies. Current in
vitro and in vivo data support an anti-inﬂammatory role for Sirt1 in
WAT (Fig. 3). In 3T3-L1 adipocytes genetic or pharmacological Sirt1
inhibition increased the expression of inﬂammatory cytokines upon
tumor necrosis factor 1 alpha stimulation, whereas Sirt1 activation had
the opposite eﬀect [133]. In agreement, genetic or antisense
oligonucleotide mediated Sirt1 deﬁciency in rodents leads to elevated
inﬂammation characterized by increased macrophage inﬁltration and
Fig. 3. Adipose tissue pathways regulated by sirtuins (SIRTs) and poly(ADP-ribose) polymerases (PARPs) based on current literature in mouse models, adipocyte cell lines and human
studies. The eﬀect of obesity on white and brown adipose tissue NAD+ levels and expression levels of SIRTs, PARPs and NAD+ biosynthesis gene nicotinamide phosphoribosyltransferase
(NAMPT) are also shown in separate boxes next to both tissues. Arrows indicate increased (↑), decreased (↓) or unchanged (−) pathway activity/gene expression level. OXPHOS;
oxidative phosphorylation.
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mRNA expression of inﬂammatory cytokines in WAT under normal
[107] and HFD conditions [101,115,117,134]. However, during long-
term HFD adipocyte speciﬁc Sirt1 deletion reduced WAT inﬂammation
in contrast to the other ﬁndings [115]. Consistent with a role for Sirt1
in repressing inﬂammation, overexpression of Sirt1 reduced WAT
macrophage inﬁltration and nuclear factor kappa B and tumor
necrosis factor 1 alpha signaling during HFD [107]. In humans, WAT
SIRT1 expression levels correlate inversely to markers of inﬂammation
in obese subjects [43,69,107]. Notably, as mentioned earlier, obesity
reduces expression of SIRT1 in WAT both in mouse and humans. This
can be likely explained by the ﬁnding that caspase-1, activated by the
inﬂammasome, promotes Sirt1 degradation [101]. Therefore,
inﬂammation and reduced Sirt1 amount appeared to be associated
with obesity and could contribute to WAT dysfunction.
The role of other SIRTs and Parps in WAT inﬂammation has been
poorly investigated. In humans, WAT SIRT5 expression levels correlate
inversely to markers of inﬂammation (Fig. 3) [43]. Deletion of Sirt7 in
mice reduced WAT inﬂammatory gene expression during HFD (Fig. 3)
[135], providing another piece of evidence for the opposite functions of
Sirt1 and Sirt7 in WAT as discussed in relation to adipogenesis.
Similarly, Parps may play a role in promoting WAT inﬂammation as
Parp1 deletion or Parp inhibitor treatment reduced interleukin-6 and
other inﬂammatory gene expression levels (Fig. 3) [123,124].
5.3.5. Adipokine secretion
Adipose tissue aﬀects other tissues involved in systemic energy
homeostasis through secretion of adipokines, most notably the satiety
hormone leptin and the insulin sensitizer adiponectin. Mitochondrial
function has been tied to adipokine secretion through studies in
cultured adipocytes showing that inhibition of mitochondrial function
reduces while activation increases the production and secretion of
adiponectin [1,2]. Obesity is characterized by increased leptin and
decreased adiponectin levels.
Initial studies with 3T3-L1 adipocytes were inconclusive in regard
to the role of Sirt1 in the regulation of adiponectin. Qiao and colleagues
showed that Sirt1 promotes adiponectin expression through deacetyla-
tion of forkhead boxO1, which facilitates the transcription factor CAAT
enhancer binding protein alpha binding to the adiponectin promoter
[136]. In contrast, Qiang and colleagues showed that Sirt1 inhibits
adiponectin secretion [137]. However, based on in vivo studies Sirt1 is
a positive regulator of adiponectin production and secretion (Fig. 3).
Genetic Sirt1 deﬁciency leads to decreased circulating adiponectin level
and gene expression in WAT during HFD whereas circulating leptin
levels were either increased [101] or unaﬀected [138] by Sirt1
depletion. SIRT1 activation has the opposite eﬀect increasing mRNA
and circulating levels of adiponectin upon aging or HFD [138,139], but
in contrast SIRT1 activation decreased circulating adiponectin level in
unchallenged conditions [140]. Sirt7 deletion reduced plasma leptin
during HFD, whereas adiponectin level was not aﬀected (Fig. 3) [135].
In obese patients expression levels of WAT SIRT1 [110,111], SIRT3
and SIRT6 [111] correlate positively to the expression of adiponectin
and its receptor (Fig. 3).
5.3.6. Systemic glucose homeostasis
Systemic glucose homeostasis is determined by the intricate
interplay of diﬀerent tissues participating in glucose metabolism.
Loss of WAT Sirt1 during aging or short to intermediate HFD in
mice leads exacerbated insulin resistance and glucose intolerance
(Fig. 3) [101,115]. Overexpression of human SIRT1 in adipose
tissue during aging has the opposite eﬀect and delays the
development of insulin resistance and glucose intolerance [126].
In humans, WAT SIRT1 and SIRT5 correlate positively with insulin
sensitivity (Fig. 3) [43,69]. Overall, WAT Sirt1 appears to be a
modiﬁer of glucose homeostasis especially in challenged conditions
such as HFD or aging. The whole-body Parp1 deletion as well as
pharmacological inhibition of Parps have been shown to improve
glucose homeostasis [13,80,81] but the role of WAT PARP activity
and other SIRTs in glucose homeostasis remains to be investigated
by future studies.
5.4. SIRT and PARP expression in BAT
All seven members of mammalian SIRT family are expressed in BAT.
The expression levels of Sirt2, Sirt4 and Sirt6 are comparable to that seen
in WAT whereas levels of Sirt1 and Sirt7 are lower and levels of Sirt3 and
Sirt5 higher in BAT by comparison to WAT [141]. Calorie restriction and
short-term food deprivation as well as cold exposure increase the
expression of Sirt1, Sirt2 and Sirt3 in BAT [105,141–144]. The knowl-
edge of factors aﬀecting the expression of other SIRTs in BAT is currently
very restricted as well as SIRT expression in human BAT. The eﬀect of
obesity on BAT Sirt expression has remained obscure.
Out of the 17 members of PARP family, Parp1-12 and Parp16 have
been shown to be expressed in BAT in mice, the expression level of
Parp5b/Tnks2 (tankyrase 2) being the highest [80]. However, it is not
known how physiological stimuli related changes in cellular energy
demand or metabolic state aﬀects the expression level of Parps in BAT
and how PARPs are expressed in human BAT.
5.5. The function of SIRTs and PARPs in BAT
5.5.1. SIRTs and brown adipocyte diﬀerentiation
The acquisition of brown adipocyte phenotype depends on the
coordinated action of transcriptional co-regulators PGC-1α PPARγ and
Prdm16. See chapter 3 for details. A limited number of studies have been
conducted to investigate the role of SIRTs in brown adipocyte
diﬀerentiation. Boutant and colleagues [127], showed that the
diﬀerentiation capacity of immortalized brown preadipocytes isolated
from homozygous Sirt1 overexpressing mice is similar to that of wild-
type cells. In contrast, Sirt3 has been shown to participate in PGC-1α
mediated activation of BAT-speciﬁc thermogenic response in diﬀerentiating
primary brown adipocytes [141,145]. In agreement, PGC-1α was not able
to fully induce the expression of thermogenic genes in response to β3-
adrenergic stimuli in Sirt3 deﬁcient brown adipocytes [146]. Thus, of the
SIRTs, Sirt3 seems to be required for the diﬀerentiation of brown
adipocytes (Fig. 3). The role of Parps in the brown adipocyte
diﬀerentiation is not yet understood.
5.5.2. Browning of WAT
Thermogenic adipocytes are not exclusive to BAT but also adipocytes
in WAT can gain thermogenic capacity through browning in response
to various stimuli, at least in rodents [147]. These cells, called beige or
brite adipocytes, show comparable amounts of UCP-1 to brown
adipocytes when stimulated. Activation of PGC-1α, PPARγ and
Prdm16 in white adipocytes also drives them towards brown
adipocyte phenotype by enhancing brown adipocyte characteristics.
Sirt1 has been shown to be an important factor in facilitating
browning of WAT by mediating Prdm16 driven activation of thermo-
genic program in white adipocytes (Figs. 1 and 3). SIRT1 deacetylates
PPARγ which leads to recruitment of coactivator Prdm16 and con-
comitant clearance of the nuclear co-repressor 1 from the PPARγ
complex, and thus, induction of thermogenic genes [148]. Qiang and
colleagues [148] showed that Sirt1 promotes browning of white
adipocytes in vivo in response to cold exposure but not under basal
conditions in diﬀerent models of increased Sirt1 activity. Deﬁciency of
Sirt1 has the opposite eﬀect and results in lower levels of BAT markers
in subcutaneous WAT in mice [138,148]. Currently, there are no
studies available of the role of other SIRTs or PARPs in WAT browning.
These processes in humans are also unclear.
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5.5.3. Whitening of BAT in obesity
Whitening of BAT results from mitochondrial dysfunction.
Therefore, as an important regulator of cellular energy homeostasis
and mitochondrial biogenesis, SIRT1 has the potential to regulate BAT
whitening. Indeed, while Sirt1 gain-of-function models lead to
browning of white adipocytes (see above), Sirt1 deﬁciency in BAT is
related to whitening of the tissue (Fig. 3). Sirt1 deﬁciency in mice
results in accumulation of lipid droplets as well as in reduction of
mitochondrial content and respiratory chain complex subunit
abundance in brown adipocytes upon HFD [138]. Moreover, adipose
tissue speciﬁc Sirt1 deletion increases the weight of BAT by increasing
its adiposity [101]. Mechanistically SIRT1 has also been shown to
control the angiogenic activity of endothelial cells [149], and thus, it
remains to be clariﬁed whether Sirt1 deﬁciency mediates BAT
whitening through aﬀecting vasculature of BAT, mitochondrial
metabolism of brown adipocytes, or both. As a whole, it seems clear
that SIRT1 is needed for the proper function of BAT. The role of other
SIRTs and Parps in whitening of BAT has been poorly investigated and
their role remains to be elucidated by future research.
5.5.4. Mitochondrial biogenesis and OXPHOS
Among the key factors activating BAT mitochondrial biogenesis and
OXPHOS are cofactors PGC-1α and PGC-1β [59]. Genetic and
pharmacological activation of Sirt1 have been shown to increase
expression and/or activity of PGC-1α and OXPHOS genes in BAT in
mice but unexpectedly this has not been translated into higher
mitochondrial content in most of the studies [71,89,90,127]. Of the
other SIRTs, SIRT3 has been suggested to play a role in the stimulation
of OXPHOS in BAT as it deacetylates and activates subunits of the
respiratory chain complex IV subunits as well as activates complex II
(SDH) [141,150]. The most potent activator of BAT mitochondrial
biogenesis and OXPHOS has been shown to be Parp1. Deletion of
Parp1 activates both PGC-1α activity and mitochondrial biogenesis,
but also OXPHOS in BAT [80]. Surprisingly, deletion of Parp2 does not
inﬂuence PGC-1α expression and mitochondrial biogenesis in BAT
despite of increased SIRT1 content [13]. Thus, it can be speculated that
maybe additional mediators, such as PGC-1β, are required in addition
to PGC-1α and SIRT1 for the activation of mitochondrial biogenesis in
some situations. In summary, SIRT1 activation likely has beneﬁcial
impacts on BAT OXPHOS while Parp1 may dampen both
mitochondrial biogenesis and OXPHOS in BAT (Fig. 3).
5.5.5. Fatty acid oxidation
SIRTs have been shown to be involved in the control of BAT fatty
acid oxidation, which is the main energy production pathway in this
tissue. Pharmacological activation of SIRT1 enhances expression of the
fatty acid oxidation promoting gene, PPARα, in BAT [90]. Moreover,
overexpression of Sirt1 leads to a strong induction of the genes
involved in fatty acid β-oxidation in BAT via activation of UCP-1,
PPARα, forkhead box O1 and forkhead box O3 [127]. It has been also
suggested that SIRT1 activation may mediate its stimulatory eﬀect on
fatty acid oxidation in brown adipocytes by enhancing the
transcriptional response to β3-adrenergic stimuli. Of the other SIRTs,
SIRT3 may enhance fatty acid oxidation by deacetylating and activating
the long-chain acyl coenzyme A dehydrogenase [142] in BAT [151].
Indeed, fatty-acid oxidation is decreased upon fasting in BAT as well as
in other peripheral tissues of Sirt3 deﬁcient mice [142]. Parp1 may
also play a role in regulating BAT fatty acid oxidation as whole-body
Parp1 deletion increases the expression of medium-chain acyl-CoA
dehydrogenase gene probably via activation of SIRT1 (Fig. 3) [80].
Overall, in the light of current data Sirt1 and Sirt3 enhance whereas
Parp1 possibly inhibits fatty acid oxidation of brown adipocytes
(Fig. 3), while the potential role of other SIRTs or Parps has not
been investigated.
5.5.6. Thermogenesis and systemic glucose homeostasis
Cold-activation increases BAT thermogenesis with concomitant
increase in glucose uptake and utilization, thus, subsequently
improving overall glucose metabolism of an organism [152,153].
Genetic and pharmacological activation of SIRT1 have been
consistently shown to increase BAT thermogenesis and improve
systemic glucose tolerance in mice [71,89,90,127,154]. In agreement,
Sirt1 deﬁciency in mice has the opposite eﬀect and results in
diminished cold tolerance and exacerbated glucose intolerance and
insulin resistance in response to HFD [138]. Sirt3 has also been
suggested to play a role in adaptive thermogenesis. Sirt3 deﬁcient mice
exhibit cold intolerance and impaired glucose metabolism during
simultaneous fasting and cold exposure [142]. Furthermore,
overexpression of Sirt3 in HIB1B brown adipocytes enhances the
expression of thermogenic genes. However, due to the lack of Sirt3
overexpression mouse model it remains to be clariﬁed whether
activation of Sirt3 can lead to beneﬁcial eﬀects on systemic glucose
metabolism. The role of SIRT6 in thermogenesis is not well understood
but Sirt6 deﬁcient mice exhibit drastic hypoglycemia due to increased
BAT uptake of glucose [155]. In contrast, Sirt7 deﬁcient mice show
increased body temperature and increased expression of thermogenic
genes in BAT along with enhanced glucose tolerance [135]. At present
the role of other SIRTs in BAT in systemic glucose homeostasis is not
known. Nevertheless, based on current data, BAT SIRT1, SIRT3 and
SIRT7 potentially participate in the control of overall glucose
homeostasis through thermogenesis (Fig. 3).
Parp1 deﬁciency leads to similar beneﬁcial eﬀects on cold tolerance
and glucose metabolism as SIRT1 activation models (Fig. 3) [80],
whereas Parp2 deletion does not aﬀect adaptive thermogenesis of BAT
[13] despite increased SIRT1 activity in BAT in both models. The role
of other Parps on activation of BAT thermogenesis and glucose
metabolism has not been investigated. Like mentioned earlier whole
body deletion of Parp1 and PARP inhibition improve whole body
glucose homeostasis [13,80,81] but as there are no BAT speciﬁc models
for Parps available, it is diﬃcult to estimate their role in the regulation
of BAT and whole body glucose metabolism conclusively.
6. Conclusions
Based on the current knowledge reviewed here we are for the very
ﬁrst time closer to understanding what is the complex mechanism
behind obesity-associated adipose tissue dysfunction; the key driver for
metabolic complications. It has recently become evident that adipose
tissue dysfunction is tightly associated with mitochondrial derange-
ments and disturbed NAD+ homeostasis. This implies that the main-
tenance of NAD+ intracellular levels and mitochondrial function is
required for adipose tissue health. Mitochondrial metabolism is
regulated by two NAD+-consuming enzyme families, SIRTs and
PARPs, which sense energy and stress status of the cell and translate
this information to mitochondria with opposing eﬀects on adipose
tissue metabolism. These two enzyme families are relevant for myriad
aspects of adipose tissue function and metabolic health. Obesity
interferes with the balance of SIRT and PARP activities in adipose
tissue, which may be one of the underlying causes for the adipose tissue
mitochondrial dysfunction and adverse metabolic health complications
associated with obesity.
In WAT SIRT1 is by far the most studied member of the SIRT
family. It appears to be involved in the regulation of several adipose
tissue processes such as adipogenesis, lipid homeostasis, inﬂammation,
adipokine secretion and the inﬂuence on systemic glucose homeostasis.
In general, SIRT1 promotes healthy adipose tissue function and
preserves systemic metabolic health. In the coming years, further
research is needed to elucidate and conﬁrm the role of other SIRTs
in WAT function. The impact of PARPs on adipose tissue health has
been less investigated and so far, the information is mainly limited to
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Parp1 and Parp2. Collectively, Parp1 and Parp2 seem to promote
adipogenesis and inﬂammation in WAT. However, we need to inves-
tigate whether other PARP family members also have important
functions in adipose tissue. Currently, another caveat in the research
ﬁeld is the lack of understanding how SIRTs and PARPs aﬀect WAT
mitochondrial function. Therefore, further research should focus on
elucidating their potential crosstalk in WAT in the regulation of
mitochondrial metabolism during normal and obese conditions. This
could solve the still open question whether the opposing eﬀects of
SIRTs and PARPs on metabolic health are mediated by alterations in
WAT mitochondrial function.
In BAT, an antagonistic crosstalk of SIRTs and PARPs in the
regulation of mitochondrial metabolism has been observed in diﬀerent
mouse models. Sirt1 and Sirt3 seem to increase mitochondrial thermo-
genesis with concomitant activation of OXPHOS and fatty acid beta-
oxidation, and improvement of systemic glucose metabolism while
Parp1 has the opposite eﬀect on BAT mitochondrial pathways. What is
lacking in the research ﬁeld, however, are studies using tissue-speciﬁc
loss-of-function and gain-of-function approaches in mice to clarify the
role of SIRTs and PARPs in the BAT metabolic health. Despite recent
improvements in the understanding of SIRTs and PARPs mitochon-
drial functions in BAT in mice, their biology and the eﬀect on
mitochondrial metabolism in humans has remained obscure. Thus,
new methods and techniques to study human BAT metabolism are
welcomed.
Increasing tissue level SIRT activity through boosting intracellular
NAD+ levels either by stimulating NAD+ synthesis with vitamin B3
derived NAD+ precursors or inhibiting PARPs is currently a focus of
intensive research as a potential treatment for obesity and associated
metabolic complications. However, improving adipose tissue metabolic
health through NAD+ restoration therapy will require further under-
standing of eﬃcacies of diﬀerent NAD+ boosters in increasing the
intracellular NAD+ levels, SIRT activity and mitochondrial function in
WAT. Importantly, future studies with NAD+ boosters should strive to
target WAT and/or BAT in mouse models and humans, as systemic
metabolic health is likely to be dependent on the concerted eﬀort of
both adipose tissues. As NAD+ precursors, vitamin B3 forms are water-
soluble vitamins, they are considered to be safe and cost-eﬀective
potential therapy options. In the coming years, new vitamin B3 based
nutritional therapies to activate SIRTs may be developed, not only for
treatment of obesity and associated metabolic complications, but also
for disease prevention and health maintenance.
Acknowledgements
The authors apologize to colleagues whose original work could not
be cited due to the vast amount of literature. The study was supported
by Academy of Finland (285963 to E.P.), Biocentrum Helsinki (E.P.),
Sigrid Jusélius Foundation (E.P.), Academy of Finland Centre of
Excellence in Research on Mitochondria, Metabolism, and Disease
(FinMIT) (272376 to K.H.P.), Academy of Finland project grant
(266286 to K.H.P.), the Novo Nordisk Foundation (K.H.P.), Finnish
Foundation for Cardiovascular Research (K.H.P.), University of
Helsinki (K.H.P.), Finnish Diabetes Research Foundation (K.H.P.)
and Helsinki University Hospital research funds (K.H.P).
Appendix A. Supplementary material
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.redox.2017.02.011.
References
[1] E.H. Koh, J.-Y. Park, H.-S. Park, et al., Essential role of mitochondrial function in
adiponectin synthesis in adipocytes, Diabetes 56 (2007) 2973–2981.
[2] C.-H. Wang, C.-C. Wang, H.-C. Huang, Y.-H. Wei, Mitochondrial dysfunction
leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes,
FEBS J. 280 (2013) 1039–1050.
[3] P. Björntorp, C. Bengtsson, G. Blohmé, et al., Adipose tissue fat cell size and
number in relation to metabolism in randomly selected middle-aged men and
women, Metabolism 20 (1971) 927–935.
[4] S. Heinonen, L. Saarinen, J. Naukkarinen, et al., Adipocyte morphology and
implications for metabolic derangements in acquired obesity, Int. J. Obes. 38
(2014) 1423–1431.
[5] L. Heilbronn, S.R. Smith, E. Ravussin, Failure of fat cell proliferation, mito-
chondrial function and fat oxidation results in ectopic fat storage, insulin
resistance and type II diabetes mellitus, Int. J. Obes. Relat. Metab. Disord. 28
(2004) S12–S21.
[6] S. Virtue, A. Vidal-Puig, Adipose tissue expandability, lipotoxicity and the
metabolic syndrome – an allostatic perspective, Biochim. Et. Biophys. Acta (BBA)
- Mol. Cell Biol. Lipids 1801 (2010) 338–349.
[7] K.H. Pietiläinen, J. Naukkarinen, A. Rissanen, et al., Global transcript proﬁles of
fat in monozygotic twins discordant for BMI: pathways behind acquired obesity,
PLoS Med. 5 (2008) e51.
[8] L.M. Pérez, A. Bernal, B. de Lucas, et al., Altered metabolic and stemness capacity
of adipose tissue-derived stem cells from obese mouse and human, PloS One 10
(2015) e0123397.
[9] V. Tormos Kathryn, E. Anso, B.R. Hamanaka, et al. Mitochondrial complex III
ROS regulate adipocyte Diﬀerentiation, Cell Metab. 14: pp. 537–544.
[10] J. Naukkarinen, S. Heinonen, A. Hakkarainen, et al., Characterising metabolically
healthy obesity in weight-discordant monozygotic twins, Diabetologia 57 (2014)
167–176.
[11] S. Heinonen, J. Buzkova, M. Muniandy, et al., Impaired mitochondrial biogenesis
in adipose tissue in acquired obesity, Diabetes 64 (2015) 3135.
[12] C. Christodoulides, C. Lagathu, J.K. Sethi, A. Vidal-Puig, Adipogenesis and WNT
signalling, Trends Endocrinol. Metab.: TEM 20 (2009) 16–24.
[13] P. Bai, C. Canto, A. Brunyanszki, et al., PARP-2 regulates SIRT1 expression and
whole-body energy expenditure, Cell Metab. 13 (2011) 450–460.
[14] R.H. Houtkooper, E. Pirinen, J. Auwerx, Sirtuins as regulators of metabolism and
healthspan, Nat. Rev. Mol. Cell Biol. 13 (2012) 225–238.
[15] D.J. Pagliarini, S.E. Calvo, B. Chang, et al., A mitochondrial protein compendium
elucidates complex I disease biology, Cell 134 (2008) 112–123.
[16] T. Wai, T. Langer, Mitochondrial dynamics and metabolic regulation, Trends
Endocrinol. Metab. 27 (2016) 105–117.
[17] M.J. Phillips, G.K. Voeltz, Structure and function of ER membrane contact sites
with other organelles, Nat. Rev. Mol. Cell Biol. 17 (2016) 69–82.
[18] C. Cantó, Z. Gerhart-Hines, J.N. Feige, et al., AMPK regulates energy expenditure
by modulating NAD(+) metabolism and SIRT1 activity, Nature 458 (2009)
1056–1060.
[19] S. Jäger, C. Handschin, J. St.-Pierre, B.M. Spiegelman, AMP-activated protein
kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α,
Proc. Natl. Acad. Sci. 104 (2007) 12017–12022.
[20] P. Puigserver, Z. Wu, C.W. Park, R. Graves, M. Wright, B.M. Spiegelman, A cold-
inducible coactivator of nuclear receptors linked to adaptive thermogenesis, Cell
92 (1998) 829–839.
[21] H. Yamamoto, E.G. Williams, L. Mouchiroud, et al., NCoR1 is a conserved
physiological modulator of muscle mass and oxidative function, Cell 147 (2011)
827–839.
[22] J. Pérez-Schindler, S. Summermatter, S. Salatino, et al., The corepressor NCoR1
antagonizes PGC-1α and estrogen-related receptor α in the regulation of skeletal
muscle function and oxidative metabolism, Mol. Cell. Biol. 32 (2012) 4913–4924.
[23] P. Li, W. Fan, J. Xu, et al., Adipocyte NCoR knockout decreases PPARγ
phosphorylation and enhances PPARγ activity and insulin sensitivity, Cell 147
(2011) 815–826.
[24] J.E. Dominy, P. Puigserver, Mitochondrial biogenesis through activation of
nuclear signaling proteins, Cold Spring Harb. Perspect. Biol. 5 (2013) a015008.
[25] P.M. Quiros, T. Langer, C. Lopez-Otin, New roles for mitochondrial proteases in
health, ageing and disease, Nat. Rev. Mol. Cell Biol. 16 (2015) 345–359.
[26] M. Karbowski, R.J. Youle, Regulating mitochondrial outer membrane proteins by
ubiquitination and proteasomal degradation, Curr. Opin. Cell Biol. 23 (2011)
476–482.
[27] V. Jovaisaite, L. Mouchiroud, J. Auwerx, The mitochondrial unfolded protein
response, a conserved stress response pathway with implications in health and
disease, J. Exp. Biol. 217 (2014) 137–143.
[28] A. Sugiura, G.-L. McLelland, E.A. Fon, H.M. McBride, A new pathway for
mitochondrial quality control: mitochondrial-derived vesicles, Embo J. 33 (2014)
2142–2156.
[29] R.J. Youle, D.P. Narendra, Mechanisms of mitophagy, Nat. Rev. Mol. Cell Biol. 12
(2011) 9–14.
[30] C. Canto, K.J. Menzies, J. Auwerx, NAD(+) metabolism and the control of energy
homeostasis: a balancing act between mitochondria and the nucleus, Cell Metab.
22 (2015) 31–53.
[31] M. Dashty, A quick look at biochemistry: carbohydrate metabolism, Clin.
Biochem. 46 (2013) 1339–1352.
[32] M.C. McKenna, H.S. Waagepetersen, A. Schousboe, U. Sonnewald, Neuronal and
astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing
equivalents: current evidence and pharmacological tools, Biochem. Pharmacol. 71
(2006) 399–407.
[33] S. Eaton, Control of mitochondrial beta-oxidation ﬂux, Prog. Lipid Res. 41 (2002)
197–239.
[34] J.R. Ussher, J.S. Jaswal, G.D. Lopaschuk, Pyridine nucleotide regulation of
cardiac intermediary metabolism, Circ. Res. 111 (2012) 628–641.
R. Jokinen et al. Redox Biology 12 (2017) 246–263
261
[35] C.J. Lynch, S.H. Adams, Branched-chain amino acids in metabolic signalling and
insulin resistance, Nat. Rev. Endocrinol. 10 (2014) 723–736.
[36] S. Heinonen, M. Muniandy, J. Buzkova, et al., Mitochondria-related transcrip-
tional signature is downregulated in adipocytes in obesity: a study of young
healthy MZ twins, Diabetologia (2016) 1–13.
[37] I. Bogacka, H. Xie, G.A. Bray, S.R. Smith, Pioglitazone induces mitochondrial
biogenesis in human subcutaneous adipose tissue in vivo, Diabetes 54 (2005)
1392–1399.
[38] H.-J. Choo, J.-H. Kim, O.-B. Kwon, et al., Mitochondria are impaired in the
adipocytes of type 2 diabetic mice, Diabetologia 49 (2006) 784–791.
[39] M. Kaaman, L.M. Sparks, V. van Harmelen, et al., Strong association between
mitochondrial DNA copy number and lipogenesis in human white adipose tissue,
Diabetologia 50 (2007) 2526–2533.
[40] T.D. Cummins, C.R. Holden, B.E. Sansbury, et al., Metabolic remodeling of white
adipose tissue in obesity, Am. J. Physiol. - Endocrinol. Metab. 307 (2014) E262–E277.
[41] J.X. Rong, Y. Qiu, M.K. Hansen, et al., Adipose mitochondrial biogenesis is
suppressed in db/db and high-fat diet–fed mice and improved by rosiglitazone,
Diabetes 56 (2007) 1751–1760.
[42] M.J. Tol, R. Ottenhoﬀ, M. van Eijk, et al., A PPARγ-Bnip3 axis couples adipose
mitochondrial fusion-ﬁssion balance to systemic insulin sensitivity, Diabetes 65
(2016) 2591–2605.
[43] S. Jukarainen, S. Heinonen, J.T. Rämö, et al., Obesity is associated with low NAD
+/SIRT pathway expression in adipose tissue of BMI-discordant monozygotic
twins, J. Clin. Endocrinol. Metab. 101 (2016) 275–283.
[44] V. Moreno-Viedma, M. Amor, A. Sarabi, et al., Common dysregulated pathways in
obese adipose tissue and atherosclerosis, Cardiovasc. Diabetol. 15 (2016) 120.
[45] P. She, C. Van Horn, T. Reid, S.M. Hutson, R.N. Cooney, C.J. Lynch, Obesity-
related elevations in plasma leucine are associated with alterations in enzymes
involved in branched-chain amino acid metabolism, Am. J. Physiol. Endocrinol.
Metab. 293 (2007) E1552–E1563.
[46] I. Dahlman, M. Forsgren, A. Sjögren, et al., Downregulation of electron transport
chain genes in visceral adipose tissue in type 2 diabetes independent of obesity
and possibly involving tumor necrosis factor-α, Diabetes 55 (2006) 1792–1799.
[47] P.W. Lindinger, M. Christe, A.N. Eberle, et al., Important mitochondrial proteins
in human omental adipose tissue show reduced expression in obesity, J. Proteom.
124 (2015) 79–87.
[48] X. Xie, Z. Yi, B. Bowen, et al., Characterization of the human adipocyte proteome
and reproducibility of protein abundance by one-dimensional gel electrophoresis
and HPLC-ESI-MS/MS, J. Proteome Res. 9 (2010) 4521–4534.
[49] M. Christe, E. Hirzel, A. Lindinger, et al., Obesity aﬀects mitochondrial citrate
synthase in human omental adipose tissue, ISRN Obes. 2013 (2013) 826027.
[50] B. Fischer, T. Schöttl, C. Schempp, et al., Inverse relationship between body mass
index and mitochondrial oxidative phosphorylation capacity in human subcuta-
neous adipocytes, Am. J. Physiol. - Endocrinol. Metab. 309 (2015) E380–E387.
[51] X. Yin, I.R. Lanza, J.M. Swain, M.G. Sarr, K.S. Nair, M.D. Jensen, Adipocyte
mitochondrial function is reduced in human obesity independent of fat cell size, J.
Clin. Endocrinol. Metab. 99 (2014) E209–E216.
[52] M. Chattopadhyay, I. GuhaThakurta, P. Behera, et al., Mitochondrial bioenergetics
is not impaired in nonobese subjects with type 2 diabetes mellitus, Metab. - Clin.
Exp. 60 (2011) 1702–1710.
[53] T. Schöttl, L. Kappler, T. Fromme, M. Klingenspor, Limited OXPHOS capacity in
white adipocytes is a hallmark of obesity in laboratory mice irrespective of the
glucose tolerance status, Mol. Metab. 4 (2015) 631–642.
[54] L. Wilson-Fritch, S. Nicoloro, M. Chouinard, et al., Mitochondrial remodeling in
adipose tissue associated with obesity and treatment with rosiglitazone, J. Clin.
Investig. 114 (2004) 1281–1289.
[55] M. Calderon-Dominguez, J.F. Mir, R. Fucho, M. Weber, D. Serra, L. Herrero, Fatty
acid metabolism and the basis of brown adipose tissue function, Adipocyte 5
(2016) 98–118.
[56] K.A. Virtanen, M.E. Lidell, J. Orava, et al., Functional brown adipose tissue in
healthy adults, New Engl. J. Med. 360 (2009) 1518–1525.
[57] E. Hondares, M. Rosell, J. Diaz-Delﬁn, et al., Peroxisome proliferator-activated
receptor alpha (PPARalpha) induces PPARgamma coactivator 1alpha (PGC-
1alpha) gene expression and contributes to thermogenic activation of brown fat:
involvement of PRDM16, J. Biol. Chem. 286 (2011) 43112–43122.
[58] P. Seale, S. Kajimura, W. Yang, et al., Transcriptional control of brown fat
determination by PRDM16, Cell Metab. 6 (2007) 38–54.
[59] M. Uldry, W. Yang, J. St-Pierre, J. Lin, P. Seale, B.M. Spiegelman, Complementary
action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat
diﬀerentiation, Cell Metab. 3 (2006) 333–341.
[60] A.E. Goodbody, P. Trayhurn, GDP binding to brown-adipose-tissue mitochondria
of diabetic–obese (db/db) mice. Decreased binding in both the obese and pre-
obese states, Biochem. J. 194 (1981) 1019–1022.
[61] J. Himms-Hagen, M. Desautels, A mitochondrial defect in brown adipose tissue of
the obese (ob/ob) mouse: reduced binding of purine nucleotides and a failure to
respond to cold by an increase in binding, Biochem. Biophys. Res. Commun. 83
(1978) 628–634.
[62] I. Shimizu, T. Aprahamian, R. Kikuchi, et al., Vascular rarefaction mediates
whitening of brown fat in obesity, J. Clin. Invest. 124 (2014) 2099–2112.
[63] G.H. Vijgen, N.D. Bouvy, G.J. Teule, B. Brans, P. Schrauwen, W.D. van Marken
Lichtenbelt, Brown adipose tissue in morbidly obese subjects, PloS One 6 (2011)
e17247.
[64] C. Vernochet, F. Damilano, A. Mourier, et al., Adipose tissue mitochondrial
dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatos-
teatosis, and cardiovascular complications, FASEB J. : Oﬀ. Publ. Fed. Am. Soc.
Exp. Biol. 28 (2014) 4408–4419.
[65] P.W. Caton, J. Kieswich, M.M. Yaqoob, M.J. Holness, M.C. Sugden, Nicotinamide
mononucleotide protects against pro-inﬂammatory cytokine-mediated impair-
ment of mouse islet function, Diabetologia 54 (2011) 3083–3092.
[66] J. Mercader, N. Granados, A. Caimari, P. Oliver, M.L. Bonet, A. Palou, Retinol-
binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat
obesity models, Horm. Metab. Res. 40 (2008) 467–472.
[67] J. Yoshino, K.F. Mills, M.J. Yoon, S. Imai, Nicotinamide mononucleotide, a key
NAD(+) intermediate, treats the pathophysiology of diet- and age-induced
diabetes in mice, Cell Metab. 14 (2011) 528–536.
[68] C. Pagano, C. Pilon, M. Olivieri, et al., Reduced plasma visfatin/pre-B cell colony-
enhancing factor in obesity is not related to insulin resistance in humans, J. Clin.
Endocrinol. Metab. 91 (2006) 3165–3170.
[69] E. Rappou, S. Jukarainen, R. Rinnankoski-Tuikka, et al., Weight loss is associated
with increased NAD+/SIRT1 expression but reduced PARP activity in white
adipose tissue, J. Clin. Endocrinol. Metab. 101 (2016) 1263–1273.
[70] M.J. Yoon, M. Yoshida, S. Johnson, et al., SIRT1-mediated eNAMPT secretion
from adipose tissue regulates hypothalamic NAD+ and function in mice, Cell
Metab. 21 (2015) 706–717.
[71] C. Canto, R.H. Houtkooper, E. Pirinen, et al., The NAD(+) precursor nicotinamide
riboside enhances oxidative metabolism and protects against high-fat diet-
induced obesity, Cell Metab. 15 (2012) 838–847.
[72] A. Nikiforov, V. Kulikova, M. Ziegler, The human NAD metabolome: functions,
metabolism and compartmentalization, Crit. Rev. Biochem. Mol. Biol. 50 (2015)
284–297.
[73] L.R. Stein, S. Imai, The dynamic regulation of NAD metabolism in mitochondria,
Trends Endocrinol. Metab. 23 (2012) 420–428.
[74] R.H. Houtkooper, C. Canto, R.J. Wanders, J. Auwerx, The secret life of NAD+: an
old metabolite controlling new metabolic signaling pathways, Endocr. Rev. 31
(2010) 194–223.
[75] J. Ratajczak, M. Joﬀraud, S.A. Trammell, et al., NRK1 controls nicotinamide
mononucleotide and nicotinamide riboside metabolism in mammalian cells, Nat.
Commun. 7 (2016) 13103.
[76] J.R. Revollo, A. Korner, K.F. Mills, et al., Nampt/PBEF/Visfatin regulates insulin
secretion in beta cells as a systemic NAD biosynthetic enzyme, Cell Metab. 6
(2007) 363–375.
[77] L. Mouchiroud, R.H. Houtkooper, J. Auwerx, NAD(+) metabolism: a therapeutic
target for age-related metabolic disease, Crit. Rev. Biochem. Mol. Biol. 48 (2013)
397–408.
[78] P. Bai, C. Cantó, The role of PARP-1 and PARP-2 enzymes in metabolic regulation
and disease, Cell Metab. 16 (2012) 290–295.
[79] P. Bai, L. Nagy, T. Fodor, L. Liaudet, P. Pacher, Poly(ADP-ribose) polymerases as
modulators of mitochondrial activity, Trends Endocrinol. Metab. 26 (2015) 75–83.
[80] P. Bai, C. Canto, H. Oudart, et al., PARP-1 inhibition increases mitochondrial
metabolism through SIRT1 activation, Cell Metab. 13 (2011) 461–468.
[81] E. Pirinen, C. Canto, Y.S. Jo, et al., Pharmacological inhibition of poly(ADP-
ribose) polymerases improves ﬁtness and mitochondrial function in skeletal
muscle, Cell Metab. 19 (2014) 1034–1041.
[82] S.B. Rajamohan, V.B. Pillai, M. Gupta, et al., SIRT1 promotes cell survival under
stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1,
Mol. Cell. Biol. 29 (2009) 4116–4129.
[83] K.M. Ramsey, J. Yoshino, C.S. Brace, et al., Circadian clock feedback cycle through
NAMPT-mediated NAD+ biosynthesis, Science 324 (2009) 651–654.
[84] L. Frydelund-Larsen, T. Akerstrom, S. Nielsen, P. Keller, C. Keller, B.K. Pedersen,
Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by
exercise, Am. J. Physiol. Endocrinol. Metab. 292 (2007) E24–E31.
[85] D. Chen, J. Bruno, E. Easlon, et al., Tissue-speciﬁc regulation of SIRT1 by calorie
restriction, Genes Dev. 22 (2008) 1753–1757.
[86] J. Song, S.F. Ke, C.C. Zhou, et al., Nicotinamide phosphoribosyltransferase is
required for the calorie restriction-mediated improvements in oxidative stress,
mitochondrial biogenesis, and metabolic adaptation, J. Gerontol. A Biol. Sci. Med.
Sci. 69 (2014) 44–57.
[87] P.W. Caton, J. Kieswich, M.M. Yaqoob, M.J. Holness, M.C. Sugden, Metformin
opposes impaired AMPK and SIRT1 function and deleterious changes in core
clock protein expression in white adipose tissue of genetically-obese db/db mice,
Diabetes Obes. Metab. 13 (2011) 1097–1104.
[88] N.J. Curtin, C. Szabo, Therapeutic applications of PARP inhibitors: anticancer
therapy and beyond, Mol. Asp. Med. 34 (2013) 1217–1256.
[89] J.N. Feige, M. Lagouge, C. Canto, et al., Speciﬁc SIRT1 activation mimics low
energy levels and protects against diet-induced metabolic disorders by enhancing
fat oxidation, Cell Metab. 8 (2008) 347–358.
[90] M. Lagouge, C. Argmann, Z. Gerhart-Hines, et al., Resveratrol improves mito-
chondrial function and protects against metabolic disease by activating SIRT1 and
PGC-1alpha, Cell 127 (2006) 1109–1122.
[91] K.C. Choi, O.H. Ryu, K.W. Lee, et al., Eﬀect of PPAR-alpha and -gamma agonist on
the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF
rats, Biochem. Biophys. Res. Commun. 336 (2005) 747–753.
[92] K.C. Choi, S.Y. Lee, H.J. Yoo, et al., Eﬀect of PPAR-delta agonist on the expression
of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes,
Biochem. Biophys. Res. Commun. 357 (2007) 62–67.
[93] K.L. Stromsdorfer, S. Yamaguchi, M.J. Yoon, et al., NAMPT-mediated NAD(+)
biosynthesis in adipocytes regulates adipose tissue function and multi-organ
insulin sensitivity in mice, Cell Rep. 16 (2016) 1851–1860.
[94] R.S. Birjmohun, B.A. Hutten, J.J. Kastelein, E.S. Stroes, Eﬃcacy and safety
of high-density lipoprotein cholesterol-increasing compounds: a meta-
analysis of randomized controlled trials, J. Am. Coll. Cardiol. 45 (2005)
185–197.
R. Jokinen et al. Redox Biology 12 (2017) 246–263
262
[95] M.T. Barbosa, S.M. Soares, C.M. Novak, et al., The enzyme CD38 (a NAD
glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced
obesity, FASEB J. 21 (2007) 3629–3639.
[96] K. Gariani, D. Ryu, K.J. Menzies, et al., Inhibiting poly ADP-ribosylation increases
fatty acid oxidation and protects against fatty liver disease, J. Hepatol. 66 (2016)
132–141.
[97] C.D. Haﬀner, J.D. Becherer, E.E. Boros, et al., Discovery, synthesis, and biological
evaluation of thiazoloquin(az)olin(on)es as potent CD38 inhibitors, J. Med. Chem.
58 (2015) 3548–3571.
[98] J.E. Drew, A.J. Farquharson, G.W. Horgan, L.M. Williams, Tissue-speciﬁc
regulation of sirtuin and nicotinamide adenine dinucleotide biosynthetic pathways
identiﬁed in C57Bl/6 mice in response to high-fat feeding, J. Nutr. Biochem. 37
(2016) 20–29.
[99] Z. Liu, L. Gan, G. Liu, et al., Sirt1 decreased adipose inﬂammation by interacting
with Akt2 and inhibiting mTOR/S6K1 pathway in mice, J. Lipid Res. 57 (2016)
1373–1381.
[100] E. Nisoli, C. Tonello, A. Cardile, et al., Calorie restriction promotes mitochondrial
biogenesis by inducing the expression of eNOS, Science 310 (2005) 314–317.
[101] A. Chalkiadaki, L. Guarente, High-fat diet triggers inﬂammation-induced cleavage
of SIRT1 in adipose tissue to promote metabolic dysfunction, Cell Metab. 16
(2012) 180–188.
[102] J. Krishnan, C. Danzer, T. Simka, et al., Dietary obesity-associated Hif1α
activation in adipocytes restricts fatty acid oxidation and energy expenditure via
suppression of the Sirt2-NAD(+) system, Genes Dev. 26 (2012) 259–270.
[103] H.Y. Cohen, C. Miller, K.J. Bitterman, et al., Calorie restriction promotes
mammalian cell survival by inducing the SIRT1 deacetylase, Science 305 (2004)
390–392.
[104] G. Laurent, N.J. German, A.K. Saha, et al., SIRT4 coordinates the balance between
lipid synthesis and catabolism by repressing malonyl CoA decarboxylase, Mol. Cell
50 (2013) 686–698.
[105] F. Wang, Q. Tong, SIRT2 suppresses adipocyte diﬀerentiation by deacetylating
FOXO1 and enhancing FOXO1's repressive interaction with PPARγ, Mol. Biol.
Cell 20 (2009) 801–808.
[106] S.J. Clark, M. Falchi, B. Olsson, et al., Association of sirtuin 1 (SIRT1) gene SNPs
and transcript expression levels with severe obesity, Obesity 20 (2012) 178–185.
[107] M.P. Gillum, M.E. Kotas, D.M. Erion, et al., SirT1 regulates adipose tissue
inﬂammation, Diabetes 60 (2011) 3235–3245.
[108] A. Kurylowicz, M. Owczarz, J. Polosak, et al., SIRT1 and SIRT7 expression in
adipose tissues of obese and normal-weight individuals is regulated by microRNAs
but not by methylation status, Int. J. Obes. 40 (2016) 1635–1642.
[109] S.B. Pedersen, J. Olholm, S.K. Paulsen, M.F. Bennetzen, B. Richelsen, Low Sirt1
expression, which is upregulated by fasting, in human adipose tissue from obese
women, Int. J. Obes. 32 (2008) 1250–1255.
[110] Y.S. Song, S.K. Lee, Y.J. Jang, et al., Association between low SIRT1 expression in
visceral and subcutaneous adipose tissues and metabolic abnormalities in women
with obesity and type 2 diabetes, Diabetes Res. Clin. Pract. 101 (2013) 341–348.
[111] A.R. Moschen, V. Wieser, R.R. Gerner, et al., Adipose tissue and liver expression
of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity, J.
Hepatol. 59 (2013) 1315–1322.
[112] E.D. Rosen, C.J. Walkey, P. Puigserver, B.M. Spiegelman, Transcriptional
regulation of adipogenesis, Genes Dev. 14 (2000) 1293–1307.
[113] L. Wilson-Fritch, A. Burkart, G. Bell, et al., Mitochondrial biogenesis and
remodeling during adipogenesis and in response to the insulin sensitizer
rosiglitazone, Mol. Cell. Biol. 23 (2003) 1085–1094.
[114] F. Picard, M. Kurtev, N. Chung, et al., Sirt1 promotes fat mobilization in white
adipocytes by repressing PPAR-[gamma], Nature 429 (2004) 771–776.
[115] R. Mayoral, O. Osborn, J. McNelis, et al., Adipocyte SIRT1 knockout promotes
PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity,
Mol. Metab. 4 (2015) 378–391.
[116] F. Xu, D. Burk, Z. Gao, et al., Angiogenic deﬁciency and adipose tissue dysfunction
are associated with macrophage malfunction in SIRT1(−/−) mice, Endocrinology
153 (2012) 1706–1716.
[117] Y. Zhou, et al., T. Song, J. Peng, SIRT1 Suppresses Adipogenesis by Activating
Wnt/β-Catenin Signaling In Vivo and In Vitro 7 (2016) 77707–77720.
[118] P. Simic, K. Zainabadi, E. Bell, et al., SIRT1 regulates diﬀerentiation of
mesenchymal stem cells by deacetylating β-catenin, EMBO Mol. Med. 5 (2013)
430–440.
[119] E. Jing, S. Gesta, C.R. Kahn, SIRT2 regulates adipocyte diﬀerentiation through
FoxO1 acetylation/deacetylation, Cell Metab. 6 (2007) 105–114.
[120] M. Cioﬃ, M. Vallespinos-Serrano, M. Trabulo Sara, et al., MiR-93 controls
adiposity via inhibition of Sirt7 and Tbx3, Cell Rep. 12 (2015) 1594–1605.
[121] E. Bober, J. Fang, C. Smolka, et al., Sirt7 promotes adipogenesis by binding to and
inhibiting Sirt1, BMC Proc. 6 (2012) P57.
[122] S. Erener, M. Hesse, R. Kostadinova, M.O. Hottiger, Poly(ADP-Ribose)polymer-
ase-1 (PARP1) controls adipogenic gene expression and adipocyte function, Mol.
Endocrinol. 26 (2012) 79–86.
[123] S. Erener, A. Mirsaidi, M. Hesse, et al., ARTD1 deletion causes increased hepatic
lipid accumulation in mice fed a high-fat diet and impairs adipocyte function and
diﬀerentiation, FASEB J. 26 (2012) 2631–2638.
[124] M. Lehmann, E. Pirinen, A. Mirsaidi, et al., ARTD1-induced poly-ADP-ribose
formation enhances PPARγ ligand binding and co-factor exchange, Nucleic Acids
Res. 43 (2015) 129–142.
[125] P. Bai, S.M. Houten, A. Huber, et al., Peroxisome proliferator-activated receptor
(PPAR)-2 controls adipocyte diﬀerentiation and adipose tissue function through
the regulation of the activity of the retinoid X receptor/PPARγ heterodimer, J.
Biol. Chem. 282 (2007) 37738–37746.
[126] C. Xu, B. Bai, P. Fan, et al., Selective overexpression of human SIRT1 in adipose
tissue enhances energy homeostasis and prevents the deterioration of insulin
sensitivity with ageing in mice, Am. J. Transl. Res. 5 (2013) 412–426.
[127] M. Boutant, M. Joﬀraud, S.S. Kulkarni, et al., SIRT1 enhances glucose tolerance
by potentiating brown adipose tissue function, Mol. Metab. 4 (2015) 118–131.
[128] P. Chakrabarti, T. English, S. Karki, et al., SIRT1 controls lipolysis in adipocytes
via FOXO1-mediated expression of ATGL, J. Lipid Res. 52 (2011) 1693–1701.
[129] P. Fischer-Posovszky, V. Kukulus, D. Tews, et al., Resveratrol regulates human
adipocyte number and function in a Sirt1-dependent manner, Am. J. Clin. Nutr.
92 (2010) 5–15.
[130] D.W. Foster, Malonyl-CoA: the regulator of fatty acid synthesis and oxidation, J.
Clin. Invest. 122 (2012) 1958–1959.
[131] Y. Kanﬁ, V. Peshti, R. Gil, et al., SIRT6 protects against pathological damage
caused by diet-induced obesity, Aging Cell 9 (2010) 162–173.
[132] M. Boutant, S. Kulkarni Sameer, M. Joﬀraud, et al., SIRT1 gain of function does not
mimic or enhance the adaptations to intermittent fasting, Cell Rep. 14 (2016)
2068–2075.
[133] Q.-Q. Lin, C.-F. Yan, R. Lin, et al., SIRT1 regulates TNF-α-induced expression of
CD40 in 3T3-L1 adipocytes via NF-κB pathway, Cytokine 60 (2012) 447–455.
[134] F. Xu, Z. Gao, J. Zhang, et al., Lack of SIRT1 (mammalian sirtuin 1) activity leads
to liver steatosis in the SIRT1+/− mice: a role of lipid mobilization and
inﬂammation, Endocrinology 151 (2010) 2504–2514.
[135] T. Yoshizawa, M.F. Karim, Y. Sato, et al., SIRT7 controls hepatic lipid metabolism
by regulating the ubiquitin-proteasome pathway, Cell Metab. 19 (2014) 712–721.
[136] L. Qiao, J. Shao, SIRT1 regulates adiponectin gene expression through Foxo1-C/
enhancer-binding protein α transcriptional complex, J. Biol. Chem. 281 (2006)
39915–39924.
[137] L. Qiang, H. Wang, S.R. Farmer, Adiponectin secretion is regulated by SIRT1 and
the endoplasmic reticulum oxidoreductase Ero1-Lα, Mol. Cell. Biol. 27 (2007)
4698–4707.
[138] F. Xu, X. Zheng, B. Lin, et al., Diet-induced obesity and insulin resistance are
associated with brown fat degeneration in SIRT1-deﬁcient mice, Obesity 24
(2016) 634–642.
[139] A.S. Banks, N. Kon, C. Knight, et al., SirT1 gain-of-function increases energy
eﬃciency and prevents diabetes in mice, Cell Metab. 8 (2008) 333–341.
[140] L. Bordone, D. Cohen, A. Robinson, et al., SIRT1 transgenic mice show
phenotypes resembling calorie restriction, Aging Cell 6 (2007) 759–767.
[141] T. Shi, F. Wang, E. Stieren, Q. Tong, SIRT3, a mitochondrial sirtuin deacetylase,
regulates mitochondrial function and thermogenesis in brown adipocytes, J. Biol.
Chem. 280 (2005) 13560–13567.
[142] M.D. Hirschey, T. Shimazu, E. Goetzman, et al., SIRT3 regulates mitochondrial fatty-
acid oxidation by reversible enzyme deacetylation, Nature 464 (2010) 121–125.
[143] L.G. Noriega, J.N. Feige, C. Canto, et al., CREB and ChREBP oppositely regulate
SIRT1 expression in response to energy availability, EMBO Rep. 12 (2011)
1069–1076.
[144] Z. Gerhart-Hines, J.E. Dominy Jr., S.M. Blattler, et al., The cAMP/PKA pathway
rapidly activates SIRT1 to promote fatty acid oxidation independently of changes
in NAD(+), Mol. Cell 44 (2011) 851–863.
[145] A. Giralt, E. Hondares, J.A. Villena, et al., Peroxisome proliferator-activated
receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an
essential component of the thermogenic brown adipocyte phenotype, J. Biol.
Chem. 286 (2011) 16958–16966.
[146] A. Giralt, E. Hondares, J.A. Villena, et al., Peroxisome proliferator-activated
receptor-γ coactivator-1α controls transcription of the Sirt3 gene, an essential
component of the thermogenic brown adipocyte phenotype, J. Biol. Chem. 286
(2011) 16958–16966.
[147] C. Tiraby, G. Tavernier, C. Lefort, et al., Acquirement of brown fat cell features by
human white adipocytes, J. Biol. Chem. 278 (2003) 33370–33376.
[148] L. Qiang, L. Wang, N. Kon, et al., Brown remodeling of white adipose tissue by
SirT1-dependent deacetylation of Pparγ, Cell 150 (2012) 620–632.
[149] M. Potente, L. Ghaeni, D. Baldessari, et al., SIRT1 controls endothelial angiogenic
functions during vascular growth, Genes Dev. 21 (2007) 2644–2658.
[150] L.W. Finley, W. Haas, V. Desquiret-Dumas, et al., Succinate dehydrogenase is a
direct target of sirtuin 3 deacetylase activity, PloS One 6 (2011) e23295.
[151] A. Giralt, F. Villarroya, SIRT3, a pivotal actor in mitochondrial functions:
metabolism, cell death and aging, Biochem. J. 444 (2012) 1–10.
[152] A. Bartelt, O.T. Bruns, R. Reimer, et al., Brown adipose tissue activity controls
triglyceride clearance, Nat. Med. 17 (2011) 200–205.
[153] B. Cannon, J. Nedergaard, Brown adipose tissue: function and physiological
signiﬁcance, Physiol. Rev. 84 (2004) 277–359.
[154] P.T. Pﬂuger, D. Herranz, S. Velasco-Miguel, M. Serrano, M.H. Tschop, Sirt1
protects against high-fat diet-induced metabolic damage, Proc. Natl. Acad. Sci.
USA 105 (2008) 9793–9798.
[155] L. Zhong, A. D'Urso, D. Toiber, et al., The histone deacetylase Sirt6 regulates
glucose homeostasis via Hif1α, Cell 140 (2010) 280–293.
[156] D.M. Erion, S. Yonemitsu, Y. Nie, et al., SirT1 knockdown in liver decreases basal
hepatic glucose production and increases hepatic insulin responsiveness in
diabetic rats, Proc. Natl. Acad. Sci. USA 27 (2009) 11288–11293.
[157] D.B. Lombard, F.W. Alt, H.L. Cheng, et al., Mammalian Sir2 homolog SIRT3
regulates global mitochondrial lysine acetylation, Mol. Cell. Biol. 24 (2007)
8807–8814.
[158] R. Mostoslavsky, K.F. Chua, D.B. Lombard, et al., Genomic instability and
aging-like phenotype in the absence of mammalian SIRT6, Cell 124 (2006)
315–329.
[159] K. Devalaraja-Narashimha, B.J. Padanilam, PARP1 deﬁciency exacerbates diet-
induced obesity in mice, J. Endocrinol. 205 (2010) 243–252.
R. Jokinen et al. Redox Biology 12 (2017) 246–263
263
